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Background: Treatment duration varies with the type of therapy and a patient’s recovery speed. Including such a
variation in randomized controlled trials (RCTs) enables comparison of the actual therapeutic potential of different
therapies in clinical care. An index, Treatment Duration Control (TDC) of outcome scores was developed to help
decide when to end treatment and also to determine treatment outcome by a blinded assessor. In contrast to
traditional Routine Outcome Monitoring which considers raw score changes, TDC uses relative change.
Methods: Our theory shows that if a patient with the largest baseline scores in a sample requires a relative decrease
by treatment factor T to reach a zone of low score values (functional status), any patient with smaller baselines will
attain functional status with T. Furthermore, the end score values are proportional to the baseline. These characteristics
concur with findings from the literature that a patient’s assessment of ‘much improved’ following treatment (related to
attaining functional status) is associated with a particular relative decrease in pain intensity yielding a final pain intensity
that is proportional to the baseline. Regarding the TDC-procedure: those patient’s scores that were related to
pronounced signs and symptoms, were selected for adaptive testing (reference scores). A Contrast-value was
determined for each reference score between its reference level and a subsequent level, and averaging all Contrast-
values yielded TDC. A cut-off point related to factor T for attaining functional status, was the TDC-criterion to end a
patient’s treatment as being successful. The use of TDC has been illustrated in RCT data from 118 chronic pain patients
with myogenous Temporomandibular Disorders, and the TDC-criterion was validated.
Results: The TDC-criterion of successful/unsuccessful treatment approximated the cut-off separating two patient
subgroups in a bimodal post-treatment distribution of TDC-values. Pain intensity decreased to residual levels and
Health-Related Quality of Life (HRQoL) increased to normal levels, following successful treatment according to TDC. The
post-treatment TDC-values were independent from the baseline values of pain intensity or HRQoL, and thus
independent from the patient’s baseline severity of myogenous Temporomandibular Disorders.
Conclusions: TDC enables RCTs that have a variable therapy- and patient-specific duration.
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Temporomandibular Disorders (TMD) are characterized
by chronic facial pain and restricted jaw movements. Ther-
apies have been evaluated in randomized controlled trials
(RCTs) after a constant period of treatment of 6 to 10 weeks
in TMD studies [1-4]. However, the duration of treatment
varies in clinical care as it depends on the type of therapy
as well as on a patient’s speed of recovery. When therapies
on TMD differ in mean duration, a constant period of
evaluation might influence an assessment of success rate
and efficacy of therapies. A short period will favour short
therapies whereas a long period might be disadvantageous
by including post-treatment changes in success rate. Thus
allowing variation of treatment duration complies with clin-
ical care and enables an unbiased comparison of the thera-
peutic potential of different therapies in RCTs. Such RCTs
are especially important for non-life threatening disorders
like TMD, which enable a stepped-care approach.
The raw change in scores of measuring instruments has
traditionally been considered rather than relative change
to determine the effect of treatment. Two conditions
characterize the raw change that is clinically relevant [5].
First, a statistically Reliable Change (RC) should exceed
the change caused by chance fluctuations, denoted as the
Smallest Detectable Difference [6,7] (SDD; thus RC >
SDD). Second, a patient should consider the change bene-
ficial [8]. A patient’s functional status corresponds with a
sufficiently low severity level of signs and symptoms. A re-
liable change in scores by which at least the upper limit of
a functional status is attained yields a criterion for a suc-
cessful treatment [9]. Such a criterion is likely concomi-
tant with beneficial change. In clinical care, a clinician will
emphasize the attainment of a functional status for ending
a treatment as being successful [10].
Routine Outcome Monitoring (ROM) has been intro-
duced in psychiatric care to assess a patient’s progress dur-
ing treatment [11]. ROMs use questionnaires as measuring
instruments and consider raw changes and normative
levels of total score values to define Reliable Change (RC)
and functional status. ROM helps a clinician to decide
when to end a treatment as being ‘successful’, i.e. if both
RC has occurred and an upper limit of functional status
has been passed.
In order to characterize therapy outcome, three types of
variables are of interest which can be obtained by a ROM-
procedure but not entirely by a traditional RCT with a
constant duration of treatment. The first variable is the
time and number of visits needed to come to the occasion
at which a patient’s treatment is ended and the decision
occurs on a successful/unsuccessful treatment. The sec-
ond variable is success rate which is based on the dichot-
omous outcome of successful/unsuccessful treatment of
various patients from a therapy group. The third variable
is therapy efficacy which is based on the magnitude of anoutcome variable of a measuring instrument averaged across
patients. A combination of data on treatment duration and
number of visits needed, success rate and therapy efficacy
are of interest for a costs-effectiveness-analysis.
ROM data allows the determination of differences in
success rate and efficacy between therapies in a more nat-
ural context than that of a traditional randomized con-
trolled trial. Like in clinical care, therapy duration need
not to be fixed and the selection of patients might be less
stringent in terms of co-morbidity. ROM data have been
used in an RCT in which the efficacy of brief therapy for
mood and anxiety disorders was compared to that of usual
treatment of longer duration [12]. Furthermore, ROM has
enabled the comparison of the outcome of treatment for
mild to moderate depression between RCTs and usual
clinical care [13].
A patient with a high level of signs and symptoms must
show a larger improvement in raw score level to pass the
Upper Limit of Functional Status (ULFS), than a patient
with lower levels. A large improvement in score level is
likely concomitant with a patient’s perception of a large ef-
fect of treatment. In contrast, a patient whose score level at
baseline is located just above ULFS (at a distance of the
Smallest Detectable Difference, SDD), and whose score level
passes just below ULFS with Reliable Change (RC > SDD),
likely perceives a smaller effect of treatment. This perceived
smaller effect may be non satisfactory for a patient when the
patient’s expectation of treatment effect is large. The ex-
pectation of, for example, patients with facial pain or
fibromyalgia regarding treatment of their symptoms is
large indeed, i.e. on average 60% for domains pain, fa-
tigue, distress or interference with daily activities [14].
A possible discrepancy between a favourable ROM out-
come and a patient’s expectation of treatment effect
might increase the risk on relapse for patients with
smaller baselines in particular.
The present paper describes a procedure of controlling
treatment duration in which relative change rather than
raw change in score levels is used. Following a score re-
duction by a constant factor, the Upper Limit of Func-
tional Status (ULFS) is then passed. Furthermore, the end
levels of patients with a small baseline level will be closer
to the zero level hence more remote from ULFS than with
a traditional ROM. Because of lower end levels, patients
with small baselines will perceive more treatment effect
with the procedure using relative change than with a trad-
itional ROM.
Findings on the relationship between decrease in pain
intensity following treatment and the patients’ assessment
of treatment effect [15], strongly suggest that using rela-
tive change for describing treatment progress is relevant
for chronic pain patients. This relationship has been ex-
amined for patients from 10 chronic pain studies in which
a randomized administration of pregabin versus a placebo
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duration and demographic characteristics. Patients were
stratified by categories of assessment of treatment effect,
and the mean change in pain intensity was determined for
each category yielding the relationship between change in
pain intensity and assessment of treatment effect. When
patients were stratified by pain intensity at baseline, the
relationship between raw change in pain intensity and
assessed treatment effect diverged for the various levels of
baseline pain. In contrast, similar relationships occurred
when relative (percentage) change in pain intensity was
considered (cf Figures six and seven in reference [15]).
Thus the degree of improvement by treatment is similarly
assessed by chronic pain patients, regardless of their base-
line of pain intensity and other differences in their back-
grounds and study conditions, when a particular relative
decrease in pain intensity has occurred.
If a successful treatment is related to a patient’s assess-
ment of, for example, ‘much improved’ or better, this as-
sessment will be related to attaining a particular relative
decrease in pain intensity. Suppose that, like in Temporo-
mandibular Disorders, the Upper Limit of Functional Sta-
tus (ULFS) of a disease or disorder is characterized by a
low level of signs and symptoms of pain and impairment
that might occasionally occur in healthy subjects. Then,
the amount of relative decrease in pain intensity which is
related to the assessment of ‘much improved’ is also likely
related to the relative decrease required to pass ULFS. A
treatment causing such a relative decrease by which signs
and symptoms become residual and the patients satisfied
(‘much improved’ or better), could then be considered as
being successful. Reversely, ULFS can be defined and sub-
sequently a constant amount of relative decrease in score
level which is required to pass ULFS, regardless of the pa-
tient’s baseline. Attaining functional status by this particu-
lar relative decrease will then yield a criterion for ending a
patient’s treatment by the clinician as being potentially
successful. This ending will then likely be related to the
patient’s perception of, in this example, ‘much improved’
or better.
An index of relative change, ‘Treatment Duration Con-
trol’ (TDC) has been developed as a tool for clinicians to
end or to continue a patient’s treatment in a randomized
controlled trial in which treatment duration can vary.
Like with a traditional ROM, the TDC-procedure yields
data on treatment duration and number of visits needed.
Furthermore, TDC, based on findings of a blinded asses-
sor, yields data on success rate and therapy efficacy. The
aims of the present paper are: (1) presenting the back-
ground of TDC, (2) showing its application to control
treatment duration in patients with myogenous Tem-
poromandibular Disorders in a way that concurs with
clinical care, and (3) its validation. The present study in-
volves TMD patients, but has potential for other chronicpain patients and even for other categories of patients for
which perception of the degree of treatment effect is re-
lated to relative change in signs and symptoms. The TDC-
criterion for a successful treatment will be validated by
examining distributions of: (i) TDC-values, (ii) scores of in-
tensity of the predominant pain in the oral system and (iii)
utility values of Health-Related Quality of Life (HRQoL)
being a variable that is entirely independent from TDC. It
will be shown that: (i) sub-samples of patients in a bimodal
distribution of TDC-values that occurred in the long-term,
correspond largely with the patient groups having a suc-
cessful and an unsuccessful treatment according to TDC;
(ii) the group of patients with a successful treatment is as-
sociated with a distribution of scores of pain intensity that
has become narrow following treatment and follow-up and
consists of residual small values, while the distribution re-
mains similarly broad in the group of patients with an un-
successful treatment, (iii) the group of patients with a
successful treatment is associated with scores of HRQoL
that have much improved while the scores from patients
with an unsuccessful treatment did not improve. The
TDC-criterion for a successful treatment was further vali-
dated by data from the literature. First, the amount of rela-
tive decrease in the scores of pain intensity in TMD
patients with a successful treatment was linked with an es-
timate of the patient’s assessment of the degree of improve-
ment. This improvement was derived from the invariant
association between relative decrease in pain intensity and
the assessment of improvement for various types of chronic
pain patients [15]. Second, the success rate of treatment
according to the TDC-criterion was compared to success
rates for myogenous TMD from the literature. A prelimin-
ary report on outcomes of therapies with variable duration
for myogenous TMD, has been published previously [16].
Methods
Patients and general procedure
The study was carried out in compliance with the Helsinki
Declaration, and approved by the University Ethics Com-
mittee (‘commissie Wetenschappelijk Onderzoek bij
Mensen’, WOM, [committee for Scientific Research on
Human subjects]) and the Board of Developmental Medi-
cine (‘Ontwikkelingsgeneeskunde’, OWG); reference: OG/
93/002. One hundred and eighteen patients with
myogenous Temporomandibular Disorders, a chronic
pain disorder, participated after providing informed con-
sent. Appendix, section ‘Inclusion and exclusion criteria of
the patients’ outlines the inclusion and exclusion criteria
(for details, see also ref [17]).
Evaluation of a patient’s status was carried out not
only by the person who carried out treatment (the ‘clin-
ician’, a dentist for dental therapies and a physiotherapist
for physiotherapy), but also by an assessor (another den-
tist) who was blinded to the type of treatment and the
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third dentist, the investigator (co-author RG), determined
the outcome TDC-values for the randomized controlled
trial, to keep the assessor blinded. All abovementioned
persons were specialists in orofacial pain and Temporo-
mandibular Disorders (TMD). When a physiotherapist
carried out treatment, a dentist who was responsible for
the patient, carried out a final evaluation as ‘clinician’.
The main characteristics of the procedure using rela-
tive change for a Randomized Controlled Trial with
myogenous TMD patients, were:
1. Baseline scores from anamnestic and clinical items
were obtained by a blinded assessor, just before
treatment and transferred by the investigator to keep
the assessor blinded;
2. Items with sufficiently large score values at baseline
(i.e. score value of at least the smallest detectable
difference, SDD. in the short term) were selected as
basic reference items for monitoring relative change
using the index TDC during treatment (by the
clinician) and during follow-up (by the investigator,
based on data from the blinded assessor). Thus
relative change was tested adaptively only for those
signs and symptoms which were pronounced.
3. Reference items of which relative change was
monitored, could be added during treatment (based
on data from the clinician) or following treatment (by
the investigator, based on data from the blinded
assessor) if their scores increased from a low level to a
high level (from below SDD in the short-term to
above SDD in the long-term). Possibly added
reference items from the clinician contributed
together with the basic reference items to the TDC-
value on which the clinician’s decision was based
when to end treatment. However, possibly added
reference items from the clinician were ignored for
determining post-treatment TDC-values so that they
were solely based on data from the blinded assessor.
The procedure of separately added reference items
allowed, like in clinical care, monitoring of late
pronounced signs and symptoms and provided data
on success rate and efficacy of treatment which were
not biased by the clinician or by inter-patient
differences in treatment duration or number of visits.
4. The following option has been added to comply with
usual clinical care and for ethical reasons: The
patient’s opinion as reflected in anamnestic items on
daily functioning of the oral system was given
priority in the treatment outcome if the index of
overall relative change (including changes related to
items from clinical tests) indicated a ‘successful’
treatment while the anamnestic items alone
indicated an ‘unsuccessful’ treatment.Background of TDC
The use of relative change in score levels enables defining
a constant factor for attaining functional status. Figure 1
depicts score levels of two patients, one with a maximally
large baseline level ‘m’ (for example of pain intensity), and
another patient with a smaller baseline ‘s’. Functional sta-
tus is related to a zone with low score levels between 0
and an Upper Limit of Functional Status (ULFS). Func-
tional status in myogenous Temporomandibular Disorders
is characterized by a low level of signs and symptoms of
pain and impairment of the oral system that might occa-
sionally occur in healthy subjects [17]. It is likely (see
Background, Discussion) that attaining such a condition
following treatment will be concomitant with a patient’s as-
sessment of ‘much improved’ or better. In order to attain
functional status for the patient with level m, this level
should decrease to at least ULFS. Such a decrease will
occur in a relative sense if treatment is so effective that
level m is decreased by the ratio between m and ULFS, fur-
ther denoted as the treatment factor ‘T’ (thus T =m/ULFS
and m decreases to ULFS by multiplying m with 1/T).
Figure 1 shows graphically that when a smaller baseline
level ‘s’ of another patient is decreased by the same factor
T, the zone of functional status is also attained for that pa-
tient, i.e. its post-treatment level drops below ULFS. Math-
ematically it follows that factor T derived from a patient
with the largest score level is applicable to any patient with
a smaller level (see legend of Figure 1). Furthermore, the
end level is proportional to the baseline.
So far, factor T applies to a single score with levels ‘m’
and ‘s’. However, a disease or disorder includes a variety of
signs and symptoms. On a particular type of scale, the
scores related to various signs and symptoms have to de-
crease to a similar low score value before a treatment can
be considered as being successful. Because in chronic pain
patients, the assessment of degree of improvement by
treatment is related to relative change in pain intensity,
relative change will be relevant for any sign and symptom
that is associated with pain. Myogenous TMD patients are
suffering from chronic pain, mainly in facial areas, which
is not caused by somatic disease [17]. All items from the
anamnestic and clinical examination in the present study
were related to intensity or frequency of pain from the
masticatory system, and to functioning of the oral system
in daily use and in clinical tests, which was impaired by
the presence of pain. Because of this general association
with pain, relative change from different items was equally
weighted for deriving a measure of global relative change.
Such a weighting is further supported by the finding that
the expectation of patients with facial pain or fibromyalgia
regarding treatment of their symptoms is constant in a
relative sense [14]. This expectation of relative reduction
of signs varied within a small range from 56% to 63%, re-
gardless of the domain of scoring (pain, fatigue, distress or
Figure 1 Score levels of two patients, with a maximal baseline ‘m’ and a smaller baseline ‘s’ respectively. ’ULFS’, upper limit of functional
status. The zone of functional status with residual score levels is located between zero and ULFS. T, treatment factor by which the maximal baseline ‘m’
is just decreased to level ULFS (by a factor 4 in this example; m decreases from 80 to 20 units). When the same factor T is applied to the smaller
baseline ‘s’of 35 units, this baseline is decreased below ULFS to ULFS/b, from 35 to 8.75 units. If factor T is tuned to the patient with baseline ‘m’, for
reaching ULFS, the end level of any smaller baseline will enter the zone of functional status when the same factor T is applied to this smaller baseline.
Mathematical proof: For the patient with level m, treatment must be so effective that m decreases at least by a treatment factor T to reach ULFS, thus:
m/T = ULFS (T > 1) [equation (1)]. The ratio between the patients’ baselines equals m/s = b (b, baseline factor, b > 1 ). Thus m = s.b and substituting s.b
for m in equation (1) yields: (s.b)/T = ULFS, thus the score level reached by factor T for the patient with baseline s is given by: s/T = ULFS/b. Level ULFS/b
(b > 1) is lower than level ULFS. Therefore, the value of factor T derived from a patient with the highest score level is applicable to any patient with a
lower level for attaining a final level that falls within the zone of functional status. The end level (ULFS/b) for the patient with initially level ‘s’ equals
(ULFS.s/m). Thus an end score will be located between zero and ULFS, proportionally with the baseline level ‘s’.
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ground (type of chronic pain, baseline level).
In order to consider all relative changes in the recovery
of individual patients, an overall factor of change has been
derived from all score changes within patients. Since ratio
values between two successive measurements lack an ap-
propriate zero point to attain a meaningful arithmetic mean
(the ‘usual’ mean), such values were transformed as
Contrast-values. Contrast-values have a zero point to which
values of an equivalent relative increase and decrease have
the same distance (Appendix, section ‘Averaging of ratio
values between scores from two times of measurement’).




= S2;i þ S1;i
 
; ð1Þ
in which S1,i is the score of the i-th item at a first visit (the
‘reference’ visit), and S2,i the score at a later visit.
Thus Contrast, being the ratio between difference and
sum, is a normalized difference between two measure-
ments. When there is no change (S2,i = S1,i), Ci is zero.
When signs or symptoms related to item i disappear
(S2,i = 0), Ci has the value of −1 [= (0 - S1,i)/(0 + S1,i)]. If
signs or symptoms worsen, Ci has a positive value(maximum: +1). Thus the possible Contrast-values vary
within a range from −1 to +1.
All patient’s Contrast (Ci) values were averaged for
each visit during treatment or follow-up, yielding a sin-
gle index, ‘Treatment Duration Control’ (TDC), related







in which n is the number of items.
A cut-off point of TDC is related to an overall value of
the treatment factor T required to attain functional status
across several items. As for factor T of a single score, data
from a patient with overall maximal signs and symptoms
(from pilot data, see below) have been used to derive the
overall factor T which is related to all scores changes
within that patient, and which is required to attain the
upper limit of functional status. An overall change by T
yields then a criterion for ending treatment in any patient
in the usual way of clinical care, i.e. by attaining functional
status across several signs and symptoms (Figure 1).
For two reasons, the use of a patient with maximal signs
and symptoms is appropriate to derive an overall value of
T for all patients. First, an accurate assessment of an overall
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number of scores is available with large values so that 0–4
point scales (used in the present study, see below) are
nearly entirely used. A patient with overall maximal signs
and symptoms had many scores (n = 32 for the patient
from the pilot data) with, in general, large values. Second,
following a change by an overall factor T derived from the
patient with maximal signs and symptoms, the end levels
of any patient will, on average, be proportional to the base
line (Figure 1). Such end levels concur with the empiric re-
lationship between relative decrease of pain intensity and
assessment of treatment effect that is independent from
pain intensity at baseline ([15], cf. Discussion).
In order to control the duration of treatment, two cut-
off values of the index TDC are necessary to comply
with clinical care. A first cut-off point (related to a
smaller factor than the overall factor T) serves to decide
whether a patient has responded sufficiently following a
treatment-specific time interval. If not, the clinician can
stop this treatment. Second, a cut-off point related to
factor T, serves to decide whether the upper limit of
functional status has passed and the treatment has be-
come potentially ‘successful’. Treatment can then be
ended before a preset upper limit of treatment duration
is exceeded.
The cut-off points of TDC in the present study were
based on scores on extent and/or frequency, using adjec-
tival 0–4 point scales (Table 1) for items which were re-
lated to pain or impairment of oral functioning. These
scores were obtained during the anamnestic and clinical
examination of the TMD patients. An anamnestic ques-
tionnaire included 5 scores of items related to daily oral
functioning, and the clinical examination included 42
scores of pain intensity during movement and clenching
tests and muscle palpation (Appendix, section ‘Scores
from anamnesis and clinical examination’). The cut-off
points of TDC derived from scores from the 0–4 points
scales were also valid for ratios in subsequent scores of
the intensity of the predominant pain in the masticatory
system from a 100 mm Visual Analogue Scale (VAS; part
of anamnesis, see Appendix). A generalized use of cut-
off points of TDC is supported by the finding that inTable 1 Adjectival 0–4 point scales for pain intensity,









0 no pain never painful never impairment
1 slight pain sometimes
painful
sometimes impairment
2 moderate pain regularly painful regularly impairment
3 severe pain often painful often impairment
4 extreme pain permanently
painful
permanently
impairmentnormalized form, clinically relevant changes in scores of
different items are similar for myogenous TMD, regard-
less of the type of scale used [18].
Appendix, section ‘Choosing two cut-off points of TDC’,
explains how the two cut-off points were chosen for TDC.
The first cut-off point was TDC= −0.212, which corre-
sponds to a decrease of 35% in a single score of pain inten-
sity at a 100 mm VAS [−0.212 = (65 – 100)/(65 + 100)].
Three decimals are used to have negligible rounding off er-
rors when C or TDC-values are transformed back. If a
patient’s TDC was larger than −0.212 (TDC > −0.212) at a
critical stage of treatment, the patient was insufficiently re-
sponsive to treatment. A less negative value than −0.212
means less change towards recovery (note that TDC= −1
with zero signs or symptoms left). The second cut-off point,
TDC = −0.379, was related to attaining functional status
(‘successful’ treatment), and corresponds to 55% decrease of
a single score of pain intensity (−0.379 = (45 – 100)/(45 +
100)). As outlined in Appendix, this second cut-off point
was based on baseline scores from a patient with overall
maximal signs and symptoms in a pilot sample of 20 pa-
tients, and on a panel opinion regarding the Upper Limit of
Functional Status, ULFS, across various items. When TDC
was ≤ −0.379, treatment became potentially successful.
Before treatment is started, the score values of the
various items might vary between low and large values.
In traditional Routine Outcome Monitoring, all scores
and their changes during treatment are included in the
multi-dimensional questionnaire used. However, for the
TDC-procedure, it is important to select basic ‘reference’
items that contribute substantially to Contrast-values
and TDC. Score values have a limited accuracy which is
reflected in the statistical value of the Smallest Detect-
able Difference (SDD). Some changes might therefore be
based on chance fluctuations. Although the raw change
is small between successive scores which are both small,
the relative change between such scores might be even
larger than the relative change between two score values
of which one is large. As a numerical example with scores
from a 0–4 point scale: the relative change between the
starting and subsequent score values ‘1’ and ‘0’ yields an
extreme Contrast-value of −1 (= (0 – 1)/(0 + 1)) while a
Contrast-value of −0.500 occurs when a score of ‘3’ de-
creases to ‘1’ (−0.500 = (1 – 3)/(1 + 3)). However, even the
largest possible raw decrease towards zero of the score
value ‘1’ from the pair ‘1’ and ‘0’ (a maximal decrease of 1
unit), might be solely due to chance fluctuations because a
decrease of 1 unit is smaller than an SDD value of, for ex-
ample, 2 units. Including such insignificant changes as
Contrast-values in TDC would create noise components
that would mask the effect of relative decreases in pro-
nounced signs and symptoms that reflect improvement
due to treatment. The value of SDD can be used as a
threshold for selecting reference items with a sufficient
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towards zero should exceed SDD [18].
Items scored on 0–4 point scales were selected before
treatment if their baseline exceeded the SDD of a single
score for a test-retest interval of one week. This SDD is
1.9 units (46.8% of the scale range [18]). Thus ‘basic ref-
erence items’ had a baseline of at least 2 units (corre-
sponding to at least ‘moderate pain’, ‘regularly painful’, or
‘regularly impaired function’; Table 1), and were related
to a patient’s pronounced signs and symptoms. The in-
tensity of the predominant pain in the masticatory sys-
tem, scored on a 100 mm Visual Analogue Scale, was
also a basic reference item.
In common clinical care it is usual that a clinician fol-
lows all pronounced signs or symptoms, including ones
that might be insignificant at baseline but become pro-
nounced during treatment. In traditional Routine Out-
come Monitoring or a traditional Randomized Controlled
Trial, the increased scores of such late pronounced signs
or symptoms are automatically included in the multi-
dimensional questionnaire used. If such scores remain large
in ROM they might ultimately contribute to an increased
overall outcome score and hence to a decreased success
rate and efficacy of therapy. In order to allow monitoring
such late pronounced signs or symptoms in the TDC-
procedure, reference items could be added during a visit
following the baseline measurements. It is then of interest
(cf. Discussion) to avoid possible bias in the TDC-related
outcome variables success rate and treatment efficacy,
which might be clinician-bound or might be due to inter-
patient differences in the number of visits or in duration of
treatment. To that end, reference items that were added
during treatment by the clinician were separately consid-
ered from those added following treatment on the basis of
data from the blinded assessor (details, see below). As an
example of addition: suppose that an item has a score value
of ‘1’ before treatment and that this score increases to ‘3’
during treatment. The increase to score level ‘3’ is relevant
because a potential decrease of 3 to 0 (3 units) during sub-
sequent treatment is larger than SDD.
Based on scores of the clinician, reference items were
added to control treatment duration appropriately, if the
patient’s scores increased during treatment from a pre-
treatment level of ‘0’ or ‘1’ (a low severity level, i.e. at
most ‘slight’ pain, ‘sometimes’ painful, or ‘sometimes’ im-
pairment; Table 1) to ‘3’ or ‘4’ (a high severity level, i.e.
at least ‘severe’ pain, ‘often’ painful or ‘often’ impair-
ment). A threshold of 3 units for the maximally possible
decrease from a score ‘3’ towards zero, exceeds the long-
term SDD of a single score being 2.2 units (54.5% of the
scale range [18]). In order to minimize the influence of
chance fluctuations in the addition procedure, the long-
term SDD value was chosen as a slightly more conserva-
tive criterion than the short-term SDD of 1.9 units usedfor selecting basic reference items. The first time an item
i was added as a reference, its Contrast-value (Ci) was
calculated using the low pre-treatment score value as a
base-line (S1,i in equation (1)) on this occasion. For ex-
ample, a pre-treatment score was ‘1’, while a score of ‘3’
was observed for the first time during a later visit. The
Ci value was then +0.500 [= (3 – 1)/(3 + 1)], in which
the positive sign reflects an increased severity of the
added item for this particular visit. The increased score
value (‘3’ in this example) was used as the reference level
(S1,i in equation (1)) for subsequent visits to describe
any relative change of severity (decrease or increase)
with respect to the visit of addition (the ‘reference visit’).
TDC is primarily used as a control variable that signals
to the clinician that a patient has entered the zone of func-
tional status. The amount of relative decrease required to
pass the upper limit of this zone, has been defined a priori,
and is thus constant. The precise value of TDC at the end
of treatment is not of interest for a clinician’s decision of a
potentially successful treatment but meeting the criterion
TDC ≤ −0.379, for sufficient relative improvement which
applies to any patient, is. Worsening signs and symptoms
related to the addition of reference items means that the
general level of a patient’s reference scores will increase
somewhat. An increased score level of basic reference
items might also be involved in this general increase at the
stage of addition, yielding an increase of the general sever-
ity level of TMD. If the possible treatment duration has
not expired and the patient is further responsive, such a
patient will still be able to attain and pass the upper limit
of the zone of functional status as long as the general score
level will remain below that of the patient with maximal
baseline values to which the cut-off point TDC = −0.379
has been tuned a priori. In accordance with clinical care,
the increase in severity level of myogenous TMD, to which
the addition of reference items is related, may extent the
duration of treatment, even when this increase is tempor-
arily. More visits are then required before a clinician can
decide, using the TDC-criterion (TDC ≤ −0.379), that a
treatment has become potentially successful. When an
increase in score value is sustained and a basic reference
item is not involved, the item with the sustained larger
score during treatment will likely also have a large score
value in the data from the assessor following treatment.
This large score will then be detected as a post-
treatment added reference item. Apart to contributing to
a possible decrease in success rate, a sustained increased
score will then yield an increase in the post-treatment
TDC-value and thus tend to decrease the efficacy of the
therapy at a group level. The effect of addition of refer-
ence items on success rate and therapy efficacy will be
shown be comparing in retrospect these parameters be-
tween different modes of addition including the mode
without addition.
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and added reference ones by using a threshold of score
values might introduce a bias in the treatment outcome
which is due to regression to the mean. Large score values
will tend to decrease rather than to increase by chance
alone. If treatment success and efficacy were solely based
on raw score values with a selection threshold, these pa-
rameters of treatment outcome would be overestimated,
particularly in patients with large baseline values. How-
ever, chance effects are neutralized when the criterion for
a successful treatment is based on a constant amount of
relative change rather than on criteria which are related to
raw change. In the TDC-procedure, patients should have
proportionally more raw decrease in the score values of
their selected reference items for attaining functional sta-
tus, the larger their baseline values are. Mathematically it
follows that bias by regression to the mean is lacking in
relative decrease of any item that contributes to TDC, in
particular when Contrast-values are used (Appendix, sec-
tion ‘Lack of bias by regression to the mean in Contrast
and TDC-values’). A lack of regression to the mean for
relative change was further demonstrated using data from
the present study. The relationship between raw difference
in post-treatment and baseline scores of pain intensity,
and baseline scores of pain intensity was examined as an
example in which regression to the mean is involved. TheTable 2 Patient example of contrast-values and the index ‘Tre
Reference item (i)
anamnesis:
(1) VAS-score of intensity of predominant pain (mm)
(2) pain of the jaws (frequency)
(3) stiffness and/or fatigue of the jaw muscles (frequency)
(4) impaired movement of the jaw (frequency)
clinical examination:
(5) pain intensity on the right side during passive jaw opening
(6) pain intensity on the left side during passive jaw opening
(7) pain intensity during palpation of the right deep masseter muscle
(8) pain intensity during palpation of the left deep masseter muscle
(9) pain intensity during palpation of the insertion of the right occipital musc
(10) pain intensity during palpation of the insertion of the left occipital musc
TDCanamnestic-items = (∑ Ci)/4 = [−0.739-0.500-0.500-1.000]/4) =
TDCclinical-items = (∑ Ci)/6 = 1.000-1.000-0.333-0.333-1.000-0.333]/6) =
TDC = (∑ Ci)/10 = [−0.739-(2 × 0.500)-(4 × 1.000)-(3 × 0.333)]/10) =
Reference item (i), item with a sufficiently large score-value (see text) of which chan
related to anamnestic questions and 6 items related to the clinical examination, thu
(‘visit 2’) than S1,i, the reference value item i that was observed for the first time at
adjectival 0–4 point scales (Table 1). Ci, Contrast-value being the ratio of the differe
index Treatment Duration Control, being the mean Contrast-value averaged across
anamnestic items and the clinical items respectively.relationship between the Contrast of pain intensity and
baseline pain intensity was examined to show that the use
of Contrast-values of pain intensity eliminated any regres-
sion. The absence of regression was further verified by
examining the relationship between post-treatment TDC-
values and the baseline of two variables that were related
to the severity of myogenous TMD: (i) the intensity of the
predominant pain in the oral system and (ii) utility values
of Health-Related Quality of Life.
Following the introduction of all score values in a
custom-made spreadsheet ((Microsoft Excel®; available on
request) the reference items (including added ones) were
automatically detected and Contrast and TDC-values were
automatically determined for each patient and the various
visits. Table 2 shows a patient example of Contrast and
TDC-values.
Pre-treatment procedure
After diagnosis, the patients were randomly allocated within
two pairs of therapies, i.e. (1) occlusal splint (n = 35) versus
physiotherapy of the masticatory system (n = 37), and (2)
occlusal adjustment (OA; n = 23) versus a combination of
occlusal splint and OA (n = 23). Conventional dental therap-
ies include splint and/or OA.
The preset lower and upper limits for the number of
visits and the treatment duration varied between theatment Duration Control’ (TDC)
Reference score (S1,i) Later score (S2,i) Contrast,









le 2 0 −1.000




ges are followed. In this example of a patient, there are 4 reference items
s 10 reference items in total (i = 1..10). S2,i, score value of item i at a later visit
an earlier visit (‘visit 1’). Except the VAS-scores, all other scores originate from
nce and sum between the second and the first score values of item i.. TDC, the
all items. TDCanamnestic-items and TDCclinical-items, mean TDC averaged across the
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and 6–30 weeks (duration).
The blinded assessor carried out an anamnestic and a
clinical examination just before the start of a patient’s treat-
ment to obtain baseline scores of TMD signs and symp-
toms (Table 3, stage 2). Using these data, a list of basic
reference items was prepared by the investigator before
treatment was started.
The anamnestic questionnaire included, apart from
a VAS-score of the intensity of the predominant pain
from the masticatory system, scores on 0–4 point
scales of other items related to daily oral functioning
(Table 1; 6 items in total; Appendix, section ‘Scores
from anamnesis and clinical examination’). The clin-
ical examination included scoring of pain intensity
during movement and clenching tests and muscle
palpation (42 items). By placing Table 1 in his or her
sight, the patient could tell the score number or in-
dicate it by finger signaling, limiting time load by the
clinical examination to 15–20 minutes.
Treatment procedure
The clinician carried out the same anamnestic and
clinical examination as the assessor at various visits
(Table 3, stage 3). For determining TDC, the clinician
not only considered the basic reference items but ac-
tually increased score values could also yield added
reference items (see above, section ‘Background of
TDC’).
Patients expressed the daily functioning of the oral sys-
tem by means of anamnestic reference items whereas clini-
cians expressed the functioning of the oral system in
clinical tests by clinical reference items. Patients assessed a
smaller degree of improvement at the end of treatment
than clinicians (cf. Results). The patient’s opinion was
therefore given more weight if the outcome from the anam-
nestic items indicated a demand for further treatment, by
application of the following ‘discrepancy rule’. If the over-
all TDC was ≤ −0.379 (successful treatment), but TDC-
anamnestic-items was > −0.212 (treatment with insufficient
effect according to the patient), the treatment was consid-
ered as unfinished or as being unsuccessful if the maximal
therapy duration was exceeded.
Depending on the TDC-outcome, the clinician con-
tinued or finished treatment within preset limits of pos-
sible therapy duration. If TDC was > −0.212 after a
treatment-specific minimum duration of treatment, the
treatment was ended because the patient was not suffi-
ciently responsive. If −0.379 < TDC ≤ −0.212, a patient
was sufficiently responsive but the treatment was con-
tinued. If TDC was ≤ −0.379 at two successive visits
with a therapy-specific interval of 3–6 weeks, while the
discrepancy rule was not applied, treatment was ended
as being potentially successful.Outcome procedure
The assessor recorded the scores, on average 4.8 weeks
(SD 4.7) after the end of treatment for all patients,
and after 6 and 12 months of follow-up for those
patients whose treatments were successful in the short-
term (Table 3, stage 4 and 5). Patients with an unsuc-
cessful treatment in the short-term had no follow-up,
because their initial treatment had to be stepped up or
changed for ethical reasons and in accordance with
clinical care.
The investigator determined the TDC-value for each
patient using the patient’s basic reference items. Further-
more, those items were added as a reference of which
the assessor’s score had increased from a level of ‘0’ or
‘1’ at baseline to a level of ‘3’ or ‘4’ at a post-treatment
visit. Possibly added reference items from the clinician
were ignored to obtain success rates of treatments and
post-treatment values of TDC related to therapy efficacy
that were solely based on data from the blinded assessor.
Furthermore, by considering the treatment period as a
black box, any bias is avoided in the post-treatment
TDC-values which might be due to inter-patient differ-
ences in the number of visits during treatment or in the
duration of treatment (cf. Discussion).
Success rate of myogenous TMD (occasionally corrected
by the aforementioned discrepancy rule) was determined
in the entire patient group, as no significant differences
occurred between therapy types.
Validation of cut-off points of TDC
The cut-off TDC=−0.379 was validated by considering dis-
tributions of TDC-values, VAS-scores of pain intensity, and
utility values of EQ-5D [19] related to Health-related Quality
of Life (HRQoL). The cut-off points TDC= −0.202 and
TDC=−0.379 were validated by data from the literature.
Statistical analysis
Statistical analyses were performed using Graphpad soft-
ware (Graphpad Prism 6.01, Graphpad Software Inc, San
Diego, CA). For each therapy, TDC based on anamnestic
items was compared with TDC from clinical items, in
two-way ANOVAs for paired observations. These TDCs
were compared at three occasions of treatment evaluation:
(1) the last visit of treatment (‘pre-end-measurement’
PEM; clinician involved), (2) the visit to determine treat-
ment outcome in the short-term (‘end-measurement’, EM;
assessor involved), and (3) the visit to determine the ul-
timate treatment outcome, finishing follow-up (‘last-meas-
urement’, LM; assessor). As EM was also LM for those
patients whose treatment was unsuccessful at EM, 24.6%
of the data was common between EM and LM. Two sep-
arate ANOVAs were therefore applied to compare TDC
from PEM with that of EM and LM respectively. When
ANOVA was significant at a level of 2.5% (Bonferroni
Table 3 Procedure of a randomized controlled trial with variable treatment duration, for myogenous TMD







anamnestic and clinical data
from clinician
post-Tx anamnestic and
clinical data from blinded
assessor
follow-up: anamnestic and clinical






TDC from clinician, using list of
investigator (data from assessor),
and possibly based on added
reference items from clinician
TDC from investigator based on
assessor’s data; short-term outcome
of RCT: if TDC ≤ -0.379 and no
*application of discrepancy rule
from anamnesis: Tx successful for
short-term RCT-outcome, and
patient continues to follow-up
(stage 5); otherwise, Tx unsuccessful
TDC from investigator, based on
assessor’s data; long-term outcome
of RCT: if TDC ≤ -0.379 and no
*application of discrepancy rule
from anamnesis: Tx successful;
otherwise, Tx unsuccessful
start of Tx by
clinician
if TDC > -0.212 (after Tx-specific
minimal Tx-duration), Tx ended
unsuccessfully (insufficiently
responsive patient), patient
referred to blinded assessor
(stage 4)
**if TDC from clinician > -0.379,
while TDC from investigator ≤
-0.379 and no *application of
discrepancy rule from anamnesis: Tx
successful for short-term RCT-outcome,
and patient continues on
observation for follow-up
(stage 5; TMD, not life-threatening)
if TDC ≤ -0.379, at two successive
visits (interval of 3-6 weeks) and
no *application of discrepancy
rule from anamnesis: Tx successful
according to clinician, patient
referred to blinded assessor
(stage 4)
otherwise, Tx continued if the
pre-set maximal treatment duration
is not exceeded; then patient referred
to blinded assessor (stage 4)
Stage 3, period of treatment (Tx) with a Tx-specific range of possible Tx-duration. Stage 5, follow-up, half a year and a year respectively following the end of a treatment that is successful in the short-term (stage 4).
TDC, the index ‘Treatment Duration Control’. TMD, Temperomandibular Disorders. *application of discrepancy rule from anamnesis: if overall TDC ≤ -0.379 (successful Tx) while TDC solely based on anamnestic items
>-0.212 (Tx with insufficient effect according to the patient), Tx was considered as being unsucessful. **this rule needed not to be applied in the present study as a discrepancy did not occur between a TDC-based
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multiple comparison tests were used to determine signifi-
cant differences between each pair of results.
A separate possible addition of reference items by the
clinician during treatment and by the investigator (based
on data from the assessor) during follow-up, and consi-
dering only the added items from the assessor, was the
standard procedure for determining success rate and post-
treatment TDC-values related to therapy efficacy. In order
to assess the effect of addition, this mode was in retro-
spect compared with two other modes, i.e. (i) a mode of
continual addition in which items are possibly added by
the clinician and subsequently by the investigator (based
on data from the assessor), are considered, and (ii) a mode
without addition, in which only the basic reference items
are considered which were obtained before treatment was
started. Frequencies of patients including those related to
success rate were compared between different conditions
in a chi-square test. Two separate one-way ANOVAs for
paired observations were applied to compare the TDC-
values (pooled across therapies) between the three modes
of addition at the two post-treatment occasions of treat-
ment evaluation, EM and LM.
Regression analysis was applied to the relationship
between TDC and baseline values of the intensity of
the predominant pain and Health-related Quality of
Life respectively to examine whether TDC depends
on baseline values of variables that are related to the
severity of myogenous Temporomandibular Disorders.
Wilcoxon’s test for paired observations was used to
examine the significance of differences between pre- and
post-treatment VAS-scores of pain intensity and utility
values of EQ-5D.
Results
TDCs based on anamnestic and clinical items
Figure 2 shows TDC-values related to anamnestic and
clinical items respectively on three evaluation occasions
(‘pre-end-measurement’, PEM, at the last treatment
visit; ‘end-measurement’, EM and ‘last-measurement’,
LM, both occasions following treatment). Two-way
ANOVAs for repeated measures showed a significant (p <
0.001-0.01) effect of the type of TDC, for the three dental
therapies. Bonferroni’s post tests showed that at PEM (in-
volvement of clinician), TDC-anamnestic was consistently
larger (p < 0.001-0.01; less negative values indicating less
improvement) than TDC-clinical. Some significant differ-
ences occurred at EM and no significant differences at
LM (involvement of assessor). The ANOVA was not
significant for physiotherapy for which the evaluation was
always carried out by another person than the physiother-
apist, i.e. the responsible dentist at PEM and the assessor
at EM and LM. However, TDC-anamnestic was signifi-
cantly larger than TDC-clinical (p < 0.05; Student’s t-testfor paired observations) at the visit before PEM, in which
the physiotherapist was involved.
Differences between TDC-anamnestic and TDC-clinical
did not depend on the level of TDC-values as regressions
between the difference and the mean of paired values were
non-significant.
The influence of added reference items
The mean number of items that contributed to TDC was
14.2 at PEM (SD 8.0, range: 2–40, n = 118 patients), and
13.8 at LM (SD 7.5). Added reference items, based on data
from either the clinician or the assessor were involved in
44.1% of the patients (n = 52). The clinician added reference
items in 30.5% of the patients (mean 3.3 items, SD 3.7,
range: 1–17, n = 36 patients) and the investigator (data from
the assessor) in 27.1% of the patients (mean 2.5 items, SD
1.6, range: 1–7, n = 33 patients). A large majority of the ref-
erence items were basic reference items in the patients with
added reference items. On average, 83.7% were basic refer-
ence items and 16.3% added reference items. Furthermore,
addition of items occurred frequently in patients whose
treatment was unsuccessful in the long-term (at LM), i.e. in
69.4% of the patients evaluated by the clinician at PEM and
in 84.4% evaluated by the assessor at LM. The number of
added reference items tended to be the largest for patients
with a moderately large number of basic reference items
(10–25 basic reference items). Addition needed never to be
applied to patients with large numbers of basic reference
items (clinician: >25; data from the assessor: >30). The
summed score level, mean level, or the total number of
scores from reference items of patients for which addition
occurred, therefore never exceeded the values of the patient
with maximal baseline values from a pilot sample, to which
the cut-off point TDC=−0.379 has been tuned (see Appen-
dix, section ‘choosing two cut-off points of TDC’). The
current sample of 118 patients included 2 patients whose
baseline values of summed score level, mean level and total
number of reference items exceeded slightly those of the pa-
tient from the pilot sample (see also Appendix). Both pa-
tients had a successful treatment in the long-term.
Figures 3A-B, shows distributions of TDC-values in
which only the added reference items from the assessor
were considered at EM and LM. This distribution became
bimodal at LM. Similar, also bimodal TDC-distributions
occurred at LM when the added reference items from
both the clinician and the assessor were considered, and
when no items were added (Figures 3C-D).
Table 4 shows the effects of three modes of addition on
success rate of treatment. Separately added items from
clinician and assessor, and only considering those from
the assessor, yielded, with the least frequent use of the dis-
crepancy rule (3.4% of the patients), the most conservative
success rate at LM. The differences between modes were,
however, small and non-significant in chi-square-tests.
Figure 2 TDC-values (mean and SEM) based on anamnestic and clinical reference items respectively (four therapies). Three occasions of
treatment (Tx) evaluation: (1) PEM, ‘pre-end-measurement’ of Tx-outcome, by the clinician at the last Tx-visit; (2) EM, ‘end-measurement’ of
Tx-outcome in the short-term, by the assessor at the first post-Tx visit, and (3) LM, ‘last measurement’ with the ultimate Tx-outcome, by the
assessor at the last post-Tx visit. TDC-values at PEM include the effect of possibly added reference items from the clinician and TDC-values at EM
and LM from solely the assessor (cf. Table 4, mode s-A). Other modes of addition, including no-addition, yielded similar results (not shown here).
The horizontal bars indicate cases of significant differences (Bonferroni’s multiple comparison tests) between TDC-anamnestic and TDC-clinical at
various times of evaluation; **, p < 0.01; ***, p < 0.001. Significant differences between occasions of evaluation (not shown) occurred only for
TDC-clinical, between PEM and LM for splint-Tx (p < 0.05) and for the combination of splint and occusal adjustment (splint + OA, p < 0.05).Note that the
values of TDC-anamnestic were similar for the three occasions of evaluation. For the dental therapies, TDC-clinical increased (less negative TDC-values
related to less improvement of the patients) at the post-Tx occasions so that TDC-clinical approached TDC-anamnestic at LM.
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ing treatment, for the three modes of addition of reference
items. These TDC-values are shown for the entire sample
of patients (n = 118) and for the sub-sample of patients
whose added reference items were at least based on data
of the assessor; n = 33), for which the inter-mode differ-
ences were the largest. The top half of Table 5 shows the
TDC-values when the initial Contrast-value of added refer-
ence items at the visit of addition was calculated with re-
spect to the baseline according to equation (1). Since the
score value of such an item had a high level of ‘3 ‘or ‘4’ at
the visit of addition, and their scores at baseline were either
‘0’ or ‘1’, the initial Contrast-value had a positive value within
a range from +0.5 (=(3 – 1)/(3 + 1) to +1 (=(3 – 0)/(3 + 0) or
(4 – 0)/(4 + 0)). The bottom half of Table 5 shows the TDC-values when a value of zero was attributed as initial
Contrast-value of added reference items. Whereas the use of
positive initial Contrast-values enhances the sensitivity of
TDC to detect cases of relapse of myogenous TMD, the
use of initial zero values might be prefered in view of equal
treatment of basic and added reference items (cf. Discus-
sion). Significant inter-mode differences occurred in all
cases (1-way-ANOVAs for repeated measures; p < 0.0001-
0.05). With positive initial Contrast-values of the added
items, the difference in TDC with respect to the mode
non-addition became large for the subgroup of patients, up
to 42% for the mode of separately added items (Table 5,
top half). With zero values as initial Contrast-value of
added items, the TDC-values of modes with addition of
reference items approached closely those of the mode non-
Figure 3 Post-treatment distributions of TDC-values. These distributions are depicted at two occasions of treatment (Tx) evaluation and with
different modes of addition of reference items. Arrow, the cut-off point TDC = −0.379 for distinguishing between a successful Tx (more negative
TDC-values to the left) and an unsuccessful Tx (less negative values to the right). Total number of patients: 118. A-B, the evolution of the
TDC-distribution from the short-term to the long-term, post-Tx; possibly added reference items from solely the assessor were included in the
TDC-values. A, TDC-distribution at EM (‘end measurement’, cf. Figure 2). B, ultimate TDC-distribution at LM (‘last measurement’). Note that the
TDC-distribution became bimodal at LM. C-D, TDC-distributions at LM, with two other modes of addition of reference items: (1) items both from
the clinician and subsequently the assessor (C), and (2) no addition (D). Note that, regardless of the way of addition, the three TDC-distributions
at LM were bimodal (B, C-D) and that these distributions were similar. Black bars, patients (3.4-7.6%) whose treatments were successful according
to the sole criterion of TDC≤ −0.379, but unsuccessful according to the ‘discrepancy rule’ (see text, section ‘treatment procedure’). See Table 4 for
the success rate at various times of treatment evaluation and various modes of addition of reference items, including the effect of application of
the discrepancy rule. Occasions of evaluation and modes of addition in this figure (A-D) corresponds with EM, s-A / LM, s-A / LM, c-A and LM, NA
respectively in Table 4.
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differences in Bonferroni’s multiple comparison tests). The
effect of using initial zero Contrast-values rather than posi-
tive Contrast-values was small and non-significant on the
success rate in the long-term, i.e. 57.6% (68/118 patients)
rather than 55.9% (66/118 patients) for the mode of separ-
ately added items.
Control on regression to the mean
A highly significant (p < 0.001) regression occurred between
the raw difference values in VAS-scores of pain intensity be-
tween, for example the last measurement (LM) and baseline,
and the baseline values (r = 0.60, n = 118) of the various pa-
tients. This significant regression, with a negative gradient,
was due, at least in part, to regression to the mean. In agree-
ment with mathematical considerations (Appendix, section
‘Lack of bias by regression to the mean in Contrast and
TDC-values’), any regression was lacking (r = 0.038) between
the Contrast-values of pain intensity at LM (ratio between
difference and sum of scores at LM and at baseline) andthe baseline scores of pain intensity. Any regression was
also lacking in relationships between TDC and the baseline
of a variable that is related to severity of myogenous TMD
in individual patients. Thus the TDC-values in the short-
term following treatment (at EM) or in the long-term (at
LM) did not depend on the level of the predominant pain
at baseline (Figure 4A). Pearson’s correlation coefficient of
these regressions was nearly zero (r = 0.013-0.066), whether
or not reference items had been added during treatment
and/or follow-up. Furthermore, the scatter of the TDC-
values was similar within the entire range of baseline values
of pain intensity. The TDC-values were also independent
from the baseline utility values of Health-related Quality of
Life (Figure 4B), a variable which is to some extent in-
versely related to severity of the myogenous TMD.
Validation of the cut-off point of TDC for deciding
successful treatment
The present study provided three ways of validation.
First, it is of interest to consider the distribution of the











n S-Tx n U-Tx Success rate
(%)
PEM A 100 18 8 92 26 78.0
PEM NA 100 18 8 92 26 78.0
EM s-A 93 25 4 89 29 75.4
EM c-A 96 22 8 88 30 74.6
EM NA 98 20 6 92 26 78.0
LM s-A 70 48 4 66 52 55.9
LM c-A 78* 40* 9* 69* 49* 58.5*
LM NA 79* 39* 6* 73* 45* 61.9*
Occasion of evaluation of treatment (Tx) success rate: PEM (clinician); EM, (assessor); LM, (assessor; cf legend of Figure 2). Mode of adding reference items: A,
added (by clinician); s-A, separately added by clinician and by investigator (based on data from assesor), and only the added reference items from the assessor are
considered in the Tx evaluation; c-A, continually added by clinician and subsequently by the investigator (based on data from assessor), and all added reference
items are considered in the Tx-outcome; NA, no addition. n TDC ≤ −0.379 and n TDC > −0.379: number of patients for which TDC ≤ −0.379 or TDC > −0.379
respectively. n discrepancy rule: number of patients with application of the ‘discrepancy rule’ (see text, section ‘treatment procedure’). n S-Tx and n U-Tx: number
of patients with a successful Tx and a unsuccessful Tx respectively. Note that n S-Tx = [(n TDC ≤ −0.379) – (n discrepancy rule)], and n U-Tx = [(n TDC > −0.379) +
(n discrepancy rule)]. Note also that the application of the discrepancy rule was occasional, i.e. for 3.4-7.6% of the patients.
Success rate (%) = (n S-Tx/118)×100% (118 = total number of patients).
*, values based on n = 89 patients who entered the follow-up at EM according to separately added reference items (s-A) from the assessor (the mode of addition
used in the RCT of the present study). Because the number of patients entering the follow-up at EM would have been slightly larger according to NA (n = 92)
than actually occurring according to s-A (n = 89), the success-rate (n S-Tx) at LM might be slightly underestimated for the mode NA. The success-rate at LM is
approximately correctly estimated for the mode c-A as the number of patients entering the follow-up was nearly the same for c-A (n = 88) as for s-A (n = 89).
Note that regardless of a possible underestimation of n S-Tx for LM, NA, the value of success-rate is the smallest for LM, s-A.
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at the last measurement (LM; Figure 3B). The first peak
(pronounced negative TDC-values) in this bimodal dis-
tribution corresponded to a great extent to patients
whose treatments were successful according to the cri-
terion of TDC ≤ −0.379. The second peak corresponded
to a great extent to patients with an unsuccessful treat-
ment (TDC > −0.379).
Second, also for comparing treatment effect of the TDC-
procedure with that of other procedures (cf. Discussion), it
is of interest to examine raw changes in pain intensity in a
traditional manner. To that end, the distributions of the
values of intensity of the predominant pain (VAS-scores)
were considered before and after treatment. The intensity
of the predominant pain in the oral system is a key out-
come variable as it is related to function impairment of
the patients suffering from myogenous TMD. The wide
pre-treatment distribution of VAS-scores of pain intensity
(Figure 5) only changed into a narrow distribution of small
post-treatment VAS-scores (p < 0.01; Wilcoxon’s test for
paired observations), for patients whose treatment was suc-
cessful at LM, using TDC. The pre-treatment distribution
did hardly change for patients whose treatment was unsuc-
cessful according to TDC (Figure 5). The percentage de-
crease in VAS-score was 90.5% (SD 16.5; n = 66), when
averaged across the various patients whose treatment was
successful.
Third, Health-related Quality of Life (HRQoL) increased
significantly (p < 0.0001; Wilcoxon’s test for pairedobservations) from 0.728 (SD 0.234) to 0.916 utility units
of EQ-5D (SD 0.143, n = 63, 3 missing pairs) for those pa-
tients whose treatment was successful at LM, using TDC.
HRQoL did not change significantly from 0.734 (pre-treat-
ment; SD 0.129) to 0.662 units (post-treatment, LM; SD
0.287, n = 48, 4 missing pairs) for patients whose treat-
ment was unsuccessful.
Discussion
Characteristics of the TDC-procedure
The current TDC-procedure includes a set of rules, i.e.
(i) those regarding adaptive item selection before, dur-
ing treatment and separately at the post-treatment occa-
sions of evaluation, (ii) the rule based on relative
decrease in scores for progressing or ending treatment,
and (iii) the discrepancy rule in which the patient’s
demand for subsequent treatment can overrule the
conclusions of the clinical examination. This TDC-
procedure approaches clinical care of myogenous TMD
to such an extent that the clinicians who participated
in the Randomized Controlled Trial of the present
study, felt confident to use TDC for deciding when to
end treatment in a standardized manner. Despite the
abovementioned rules which may influence treatment
outcomes in specific ways, it is still possible to compare
treatment effect between the current TDC-procedure
with that of other procedures, even ones which differ
considerably, i.e. a traditional Routine Outcome Monitoring
or a traditional Randomized Controlled Trial. To that end,
Table 5 TDC-values for different modes of addition and initial Contrast-values of reference items
Group Occasion Mode of addition % difference relative to NA Test p-
levels-A c-A NA s-A c-A
use of positive value relative to baseline as initial Contrast-value for added reference items
all EM -0.635 -0.653 -0.659 3.6 1.0 s-A vs. NA ***
patients (0.300) (0.283) (0.270) c-A vs. NA ns
n = 118 s-A vs. c-A ***
all LM -0.541 -0.556 -0.585 7.5 4.9 s-A vs. NA ****
patients (0.339) (0.324) (0.298) c-A vs. NA *
n = 118 s-A vs. c-A **
patients with EM -0.420 -0.454 -0.514 18.2 11.8 s-A vs. NA ****
added items (0.333) (0.309) (0.276) c-A vs. NA **
from assessor s-A vs. c-A **
n = 33
patients with LM -0.229 -0.268 -0.395 42.0 32.0 s-A vs. NA ****
added items (0.281) (0.271) (0.254) c-A vs. NA ***
from assessor s-A vs. c-A **
n = 33
use of zero as initial Contrast-value for added reference items
all EM -0.651 -0.665 -0.659 1.2 -1.0 s-A vs. NA **
patients (0.274) (0.262) (0.270) c-A vs. NA ns
n = 118 s-A vs. c-A **
all LM -0.570 -0.583 -0.585 2.5 0.3 s-A vs. NA ***
patients (0.303) (0.293) (0.298) c-A vs. NA ns
n = 118 s-A vs. c-A *
patients with EM -0.485 -0.498 -0.514 5.6 3.1 s-A vs. NA **
added items (0.274) (0.267) (0.276) c-A vs. NA ns
from assessor s-A vs. c-A ns
n = 33
patients with LM -0.342 -0.357 -0.395 13.3 9.5 s-A vs. NA ***
added items (0.230) (0.225) (0.254) c-A vs. NA *
from assessor s-A vs. c-A ns
n = 33
mean and (between brackets) SD values of TDC for two ways of attributing an initial Contrast-value of an added reference item at the visit of addition, i.e. (i) by
calculating the Contrast between the large score value at addition with respect to the low value at baseline using equation (1) (see text), or (ii) by attributing the
value zero as initial Contrast-value (cf. Discussion). For explanation of the abbreviations under ‘occasion’ and ‘mode of addition’, see Table 4. Test: Bonferroni’s
multiple comparison test which could always be applied as all 1-way ANOVAs for repeated measures were significant (p < 0.0001-0.05). p-level: ****, p < 0.0001;
***, p < 0.001; **, p < 0.01; *, p < 0.05; ns, non-significant.
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traditional manner. Two parameters of raw change in out-
come variables are of interest in this respect, i.e. Clinically
Important Difference (CID) and Cohen’s Effect Size (ES).
CID is the mean raw change in an outcome variable ob-
served in a patient sample after interventions of known effi-
cacy [20]. The ratio between the mean change following atherapy and the SD of the baseline scores is ES for this ther-
apy [21,22]. A value of ES of 0.2 or less represents a small
change, a size of 0.5 represents a moderate large change
and a value of 0.8 or larger corresponds with a large effect
of therapy. Apart from comparing different therapies within
the same procedure, for example a traditional Randomized
Controlled Trial, CID and ES can also be used to compare
Figure 4 Relationships between TDC-values and baseline values of intensity of predominant pain from the masticatory system (A) and
general Health-related Quality of Life (B). These baseline values are related to the severity of myogenous Temporomandibular Disorders in
individual patients; the values of HRQoL in an inversely way. The TDC-values are from the last evaluation visit at LM (last measurement) following
treatment and include possibly a separate addition of reference items by clinician and investigator (based on data from assessor) and considering
only the added items from the assessor. For TDC = 0, an overall change in signs and symptoms is lacking following treatment and for TDC = −1
all signs and symptoms of myogenous TMD have disappeared. Solid lines, regression lines: TDC = 0.00047.PI – 0.560, in which PI is pain intensity
(Pearson’s correlation coefficient: r = 0.031, not significant, n = 118), and TDC = 0.0245.HRQoL-0.564, in which HRQoL is Health-related Quality of
Life (r = 0.015, not significant, n = 112, 6 missing values). Similarly, no significant relationships were observed for TDC from the end measurement
(EM) following treatment in the short-term and for other modes of addition of items, including no-addition. Note that significant regressions are
lacking while the scatter in TDC-values is similar within the range of baseline values, indicating that (i) the TDC-values from individual patients are
independent from their baseline values of pain intensity or HRQoL, and (ii) a similar variety of relative change following treatment occurs for the
various patients, regardless of the baseline severity of myogenous TMD. The fraction of patients whose TDC-value has dropped to or beyond the
cut-off level of −0.379 and thus the chance of attaining functional status, is independent from the patient’s baseline severity level.
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treatment. CID with its mean and SD values is then
suitable for statistical testing of efficacy between
different procedures. When CID and ES are applied
to an entire patient sample, these parameters refer to
an overall procedure effect, regardless of how the
patients are divided in a procedure-specific way into
two groups, with a ‘successful’ and an ‘unsuccessful’
treatment.
The effect of the current TDC-procedure is large for
myogenous TMD, i.e. Cohen’s effect size (ES) is 1.09 and
1.38 for rating of pain behaviour or pain intensity respect-
ively [18]. Thus the current TDC-procedure has proven to
be effective for patients who were, like in a traditional Ran-
domized Controlled Trial, selected using stringent criteria
(Appendix, ‘Inclusion and exclusion criteria of the patients’,
[17]). ES observed in myogenous TMD patients is similar
to an ES of 0.80 and 1.38 ([23], based on disability due to
pain) for patients receiving physical therapy for low back
pain [24] or acute shoulder pain [25] respectively.
TDC deals with multiplication factors of relative change
in score values rather than with these values themselves.
TDC is therefore not bound to a particular scale, and arbi-
trary weighing of score values from different items is
avoided (cf. Appendix, section ‘averaging of ratio values be-
tween scores from two times of measurement’). On the
other hand, the multiplication factors related to relative
change of different items have been equally weighted. Therationale of this equal weighing was that all items were re-
lated to intensity or frequency pain from the masticatory
system, and to disability of this system due to the presence
of pain. Furthermore, equal weighing is supported by the
finding that the expectation of patients with facial pain or
fibromyalgia regarding treatment of their symptoms is con-
stant in a relative sense for several domains of scoring [14].
Apart from a 100 mm VAS for intensity of predomin-
ant pain, adjectival 0–4 point scales (giving a choice be-
tween 5 states) have been used for all other items to
reduce the time-load of patient and clinician. Such
scales are sufficiently graded for myogenous TMD as
the mean treatment effect is large for this disorder, i.e.
Cohen’s effect size is 1.09-1.38 (see above). The accur-
acy gain of more detailed scales is limited because sub-
jects are mentally able to handle only five to nine levels
and will thus mentally reduce more detailed scales to
about seven segments [26,27]. The discrete score values
are on an ordinal rather than an interval or ratio scale
level. However, as the underlying phenomenon (dis-
order activity) is on an interval scale, these measures
can be analyzed parametrically if the sample size is
large enough (central limit theorem). Because TDC is a
mean of several Contrast-values, the gradation of TDC-
values is larger than that of Contrast-values.
The influence of random fluctuations on TDC is lim-
ited by selecting items for an adaptive way of testing,
using values of the smallest detectable difference (SDD)
Figure 5 Distributions of VAS-scores of the intensity of predominant pain from the masticatory system. n, number of patients. S-Tx and
U-Tx, patients with a successful treatment in the long-term (A-B), and an unsuccessful treatment (C-D), according to TDC based on data from the
assersor and an occasional use (3.4%) of the discrepancy rule. Pre-Tx, pre-treatment VAS-scores (A,C); Post-Tx, post-treatment VAS-scores (B,D)
from the last evaluation visit at LM (‘last measurement’).
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tion does not introduce a risk on introducing bias by re-
gression to the mean in the TDC-values. Time effects by
chance are neutralized when the criterion for a success-
ful treatment is based on a constant amount of relative
change rather than on criteria which are related to raw
change. Regression is lacking in the relationship be-
tween the Contrast-value of a single variable and its
baseline and the bandwidth of scatter in the Contrast-
values is constant (cf. Appendix, section ‘Lack of bias by
regression to the mean in Contrast and TDC-values’).
Hence, Contrast-values of any item that contributes to a
TDC-value are independent from their baseline values.
As each of the items which are involved in the mean
Contrast-value (hence the TDC-value) is related to the
baseline level of severity of myogenous TMD, a regres-
sion will also be lacking in the relationship between
TDC and baseline values of items like predominant pain
of the masticatory system (VAS-scores) and Health-
related Quality of Life (EQ-5D utility units). A lack of
such a regression has been observed indeed (Figures 4
A-B). The constant bandwidth of scatter of the post-
treatment TDC-values around the nearly horizontal re-
gression line means that a similar variety of TDC-values(similar variety of relative change) from different pa-
tients occurs, regardless of the severity level of the pa-
tients’ myogenous TMD. Hence, the fraction of patients
whose TDC-value has dropped to or beyond the cut-off
level of −0.379 and thus the chance of attaining func-
tional status, are independent from the patient’s baseline
severity level.
Also related to selecting items in an adaptive way, one
might question whether statistically, an overall reliable
change (RC > SDD for score means) can be achieved in
patients with a low baseline, who have only reference
items of ‘2’ of which some scores decrease by merely one
unit rather than consistently by two units. This problem
has been avoided in the present study by requiring a low
general score level (reflected as TDC ≤ −0.379) during
subsequent occasions of treatment evaluation rather than
at one occasion in the traditional concept of RC related to
SDD. A patient’s general score level had to be low at the
last two occasions of the clinician’s evaluation before treat-
ment was considered as being potentially successful.
Subsequently, the general score level had to be low at
three successive post-treatment times of the assessor’s
evaluation (5 weeks, 6 and 12 months after treatment), be-
fore treatment was ultimately considered as being
van der Glas and van Grootel BMC Medical Research Methodology 2013, 13:123 Page 18 of 31
http://www.biomedcentral.com/1471-2288/13/123successful. A repeated end evaluation will also correct a
single decision of a ‘successful’ treatment which might be
false due to intra-subject variation.
The current sample of 118 patients included 2 patients
whose general level of baseline scores was somewhat
higher than that of the patient from the pilot sample whose
general baseline level was used for tuning the cut-off value
TDC = −0.379. The mean score level of these 2 patients,
averaged across the reference items, was only slightly larger
than the one of the patient used for tuning the cut-off
point, because the mean level was largely dominated by
many maximal score values of 4 units (cf. Appendix, sec-
tion ‘choosing two cut-off points of TDC’). The TDC-value
required to attain the zone of functional status for these
patients was therefore only slightly more negative than
TDC=−0.379, hence the required treatment factor T was
only slightly larger. One might argue that the decision of a
successful treatment of these 2 patients might have been
favoured by the use of a slightly less conservative cut-off
value TDC=−0.379. However, the criterion TDC ≤ −0.379
for a successful treatment has been used in combination
with the discrepancy rule in which the patient’s demand for
subsequent treatment can overrule the conclusions of the
clinical examination. Such a combined use is actually more
effective than a more negative TDC-value as cut-off. Apart
from enabling further treatment for patients with such a de-
mand, the combined use prevents over-treatment of some
patients who would have been classified as being unsuccess-
fully treated using a more conservative cut-off value of TDC
while these patients had no demand for further treatment in
the current procedure (cf. section ‘validation’ below). Thus
the TDC-procedure has been proven to be robust.
The baseline data of a traditional Routine Outcome Mon-
itoring (ROM) include all scores regardless of their level. In
accordance with common clinical care, large scores related
to items of late pronounced signs or symptoms are auto-
matically included in the overall outcome variable of such
ROM and might influence treatment duration, success
rate and efficacy of a therapy. Such large scores might also
be included in the outcome variable of a traditional Ran-
domized Controlled Trial (RCT) of which the treatment
duration is constant, and influence success rate and ther-
apy efficacy. While the influence of scores which are tem-
porarily large during the treatment will wane in the
outcome variable of a traditional ROM or RCT, only
scores that are sustained large beyond the end of treat-
ment, and scores which become large during a follow-up
will influence the post-treatment outcome variable related
to these procedures.
The baseline scores of the TDC-procedure are adaptively
selected for being sufficiently pronounced. Reference items
related to late pronounced signs and symptoms must be
added later during treatment and follow-up to comply with
common clinical care to follow any item with a high levelof severity and serving the safety of patients who partici-
pate in a randomized controlled trial. The overall effect of
added reference items is small in the present study because
even in the fraction of patients (44.1%) in which addition
of reference items occurred, there were much more basic
reference items involved (84%) than added reference items
(16%). Furthermore, addition of reference items was, in
general, concomitant with increased score levels of basic
reference items. Such an increase in the general severity
level of the patient’s myogenous TMD is reflected in mean
levels of post-treatment TDC that, regardless of the mode
of addition, are clearly larger (less negative, indicating less
improvement) for a subgroup of patients with added refer-
ence items, than for the entire patient sample (Table 5).
Addition of reference items therefore occurred more fre-
quently in patients whose treatment was unsuccessful, for
example, in 84% of such patients at the last post-treatment
measurement. Thus, even in patients with added items,
relative changes in the basic reference items dominate the
outcome.
The increase in severity level of myogenous TMD, to
which the addition of reference items during treatment is
related, will extent the duration of treatment even when
this increase is temporarily. More visits are then required
before a clinician can decide, using the TDC-criterion
(TDC ≤ −0.379), that a treatment has become potentially
successful.
As the addition of reference items occurred only in
patients who had a moderately large number of basic
reference items at most, their general score level
remained below that of the TMD patient with maximal
baseline values from the pilot sample to which the treat-
ment factor T was tuned a priori. Thus the criterion of
reaching the zone of functional status following an over-
all decrease in score values by at least the treatment fac-
tor T (reflected as TDC ≤ −0.379), remains valid for
patients with added items.
In the current Randomized Controlled Trial with TDC,
the initial Contrast-value of an added reference item was
determined with respect to its basic value using equation
(1). Since the score value of such an item was either ‘3’ or
‘4’ at the visit of addition, and their baseline score values
were either ‘0’ or ‘1’, the initial Contrast-value varied within
a range from +0.5 to +1.0, where the positive sign reflects a
worsening with respect to baseline. Attributing such a
positive Contrast-value will enhance the sensitivity of TDC
to detect cases of relapse as this Contrast must be compen-
sated by negative Contrast-values from several other items
(reflecting improvement for these items) before the criter-
ion TDC ≤ −0.379 might be attained for a successful treat-
ment. The positive Contrast-value will decrease to zero
when the patient does not improve for that item, and will
have a negative value when the patient has improved at a
visit following the visit of addition. Thus even if the initial
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cisive for non-attaining functional status, a decrease to zero
or to a negative value during a subsequent visit will en-
hance the chance on attaining functional status at a later
phase of treatment.
In contrast to an addition before the end of treatment,
the initial positive Contrast-values of reference items that
are added at the last visit of treatment or at the one of the
post-treatment occasions will have a relatively large weight
in the parameters of treatment outcome (success rate and
treatment efficacy) at the end of treatment or following
treatment respectively. If the initial positive Contrast-
value is decisive for a post-treatment outcome of a non-
successful treatment, a subsequent visit for improvement
is lacking because a further follow-up was ended as soon
as a patient’s treatment was considered as being unsuc-
cessful at one of the three occasions of post-treatment
evaluation. Although not significant, the success rate
therefore tends to be lower for the mode of separately
added items in which only added items based on data
from the assessor are considered with respect to the mode
of continued added items from clinician and assessor, or
to the mode of non-addition (Table 4). Furthermore, the
post-treatment values of TDC (treatment efficacy) are sig-
nificantly larger (less negative; less improvement) for the
mode of separately added items.
In accordance with clinical care, the initial treatment of
myogenous TMD patients, suffering from chronic pain,
was stepped up or changed for ethical reasons, when this
treatment (which could have a duration within a range
from 6 to 30 weeks) appeared to be unsuccessful at a post-
treatment occasion of evaluation. Hence, a waiting period
was not applied for these patients to complete the follow-
up of a year during which spontaneous improvement might
have occurred in some patients. Thus regardless of the pro-
cedure used for treatment evaluation, including the TDC-
procedure, not completing the follow-up of all patients will
yield some bias in success rate and therapy efficacy, i.e. both
parameters will probably be slightly underestimated.
Once an item has been added as a reference item in the
TDC-procedure its Contrast-values remain to contribute
to the TDC-values of subsequent visits, also if the score
value of that item wanes to zero (its Contrast-value be-
comes then −1). When the same item is detected as an
added reference item during treatment as well as at the
first post-treatment visit, its Contrast-value at the first
post-treatment visit might differ between the modes of sep-
arately added reference items from clinician and assessor
and continued added items respectively. This inter-mode
difference occurs in particular when the initial Contrast-
value of the added item is determined with respect to the
baseline. For example, suppose that the clinician ob-
serves a score value of ‘4’ at a treatment visit of an item
of which the baseline is ‘0’, the initial Contrast-value isthen +1 (=(4 – 0)/(4 + 0) at the treatment visit of
addition. Suppose that the assessor also observes a
score value of ‘4’ at the first post-treatment visit. If the
treatment period is considered as a black box (as in the
mode of separately addition of reference items), the ini-
tial Contrast-value with respect to baseline is again +1
at the post-treatment visit. On the other hand, the
Contrast-value is not +1 but zero in the mode of con-
tinued added items (no separation of item information
between treatment and post-treatment period), with re-
spect to the score value at the visit of addition during
treatment (=(4 – 4)/(4 + 4)). This zero value reflects no
change in score value between the post-treatment visit
and the treatment visit of addition. Thus the possible
difference in post-treatment Contrast-values of added re-
ference items yields some inter-mode bias in the post-
treatment TDC-values, which has, however only a small
and non-significant effect on success rate (Table 4). Success
rate is hardly affected because attaining or passing the
TDC-level of −0.379 is decisive for considering treatment
as being potentially successful rather than the TDC-value it-
self. Thus possible inter-mode variations are irrelevant in
view of success rate, for TDC-values which are sufficiently
remote from the cut-off level of −0.379. Although small in
the entire patient sample (<3%, Table 5, top), the inter-
mode bias has a significant effect on the post-treatment
TDC-values as a measure of therapy efficacy.
Using the mode of separately added reference items
makes the post-treatment TDC-related outcome vari-
ables free from any possible clinician-bound bias. One
might argue that a clinician-bound bias would also be
avoided when the anamnestic and clinical examinations
of a patient would solely be carried out by a blinded as-
sessor, also at the treatment visits. The investigator or a
computer system could transfer the score and TDC in-
formation to the clinician to keep the assessor blinded.
A continued mode of addition of reference items could
then be applied while avoiding a possible clinician-bound
bias as well as an inter-mode bias of addition. However,
for two reasons, even an improved mode of continued
addition is not appropriate for a Randomized Controlled
Trial which uses TDC and allows variation in the number
of visits and the duration of treatment.
First, apart from a more time consuming thus less
feasible procedure for the assessor there might be a risk
on a less natural interaction between clinician and pa-
tient which might influence treatment outcome. While
this risk might be present for chronic pain patients
whose data of evaluation originates in part from man-
ual clinical tests, such a risk is absent when exclusively
questionnaires are used of which the data are collected
by a person who is neither a clinician nor an assessor,
like in Routine Outcome Monitoring of psychiatric pa-
tients [11-13].
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with large score values, transient ones in particular, may
depend on the frequency of visits and the duration of treat-
ment. For example, suppose that a sign or symptom, which
is related to a potential added reference item, reaches a
high level for a short time. The likelihood of detecting the
high score level of such an item is then larger with a higher
frequency of visits. Furthermore, suppose that the scores of
more items are transiently increased. With a particular fre-
quency of visits, detection of one of these items will then
occasionally occur when the timing of a high score level
coincides with that of a measurement. Such a coincidence
will occur more likely with a longer duration of treatment.
The therapies used in the current Randomized Controlled
Trial differed in a therapy- and patient-specific way in
number of visits and in treatment duration. Although nei-
ther the frequency of addition nor the number of added
items differed significantly between therapies at the end of
treatment, application of the mode of separately added ref-
erence items from clinician and assessor, is a sine qua
none. Thus the treatment period was considered as a black
box in the present study for determining the post-
treatment TDC values, to avoid any bias which might be
due to variation in number or frequency of visits and dur-
ation of treatment. Furthermore, the number of post-
treatment visits for treatment evaluation by the assessor
and their intervals were the same for the various therapies.
As explained before, the mode of separately added refer-
ence items yields an inter-mode bias of the post-treatment
TDC-values when the baseline of an added reference item
is used for determining its initial Contrast-value. Below it
will be shown that by using zero as an initial Contrast-
value, which can be theoretically expected, the inter-mode
bias is largely diminished.
Basic reference items and added ones have been un-
equally treated in the current TDC-procedure with respect
to the reference score value used for determining Contrast-
values. For basic reference items, the Contrast-values have
always been determined with respect to the same reference
score values from the visit at which the items were
detected as reference items, i.e. the values for the pre-
treatment ‘visit’. In contrast, two reference values have
been used for an added reference item, i.e. (1) the pre-
treatment score value for the Contrast-value at the visit of
addition and (2) the score value from the visit of addition
(visit of detection) for Contrast-values at subsequent visits
(the second situation is equivalent to that of basic reference
items). The use of a reference score value can be confined
to the same value from the visit of addition by considering
which Contrast-value should be applied within the visit of
addition, from a theoretical point of view. A patient has a
particular pattern of levels of signs and symptoms at a par-
ticular moment within a visit. This level pattern is related
to an intrinsic score pattern which becomes knownfollowing measurement. It is then also known which items
will become added reference items. Measurement, for ex-
ample, scoring of pain intensity during palpation of a sore
jaw muscle can only be carried out once within a visit be-
cause the outcome of a second measurement will be
influenced by the first one. However, even without a sec-
ond measurement, it is known that the intrinsic score pat-
tern of a second moment will be identical to the first
intrinsic pattern if the interval between the two moments
is infinitely small. Hence, with no change in the intrinsic
score values, the Contrast-value of any added reference
item will be zero between the second and the first moment.
A zero Contrast-value could also be attributed to basic ref-
erence items at the pre-treatment ‘visit’ of their detection.
Thus all reference items, basic ones as well as added ones,
are treated equally regarding the use of their reference
values, if the initial Contrast-value at the reference visit is
set to zero.
The post-treatment TDC-values are clearly less negative
for the mode of separately added reference items than for
the mode of continued added items or the mode of no-
addition, when the initial Contrast-value has a positive
value, i.e. the one with respect to the baseline (Table 5,
top). When initially zero Contrast-values are used for
added reference items, the difference in the post-
treatment TDC-values becomes marginal between the
modes of separately added items and the mode of contin-
ued added items (2.2% for the entire sample, <4% for a
sub-sample with added items, Table 5, bottom). Thus the
inter-mode bias in the TDC-values which occurs when
the Contrast-values of added reference items have initially
a positive value, is largely eliminated by the use of initial
zero Contrast-values. The TDC-values with added items
approach then even closely the TDC-values without
added items. The success rate at the last post-treatment
visit becomes also slightly less conservative by using ini-
tially zero Contrast-values, i.e. 57.6% (68/118 patients) ra-
ther than 55.9% (66/118 patients) for the mode of
separately added items.
Hence, the use of initially zero Contrast-values for
added reference items is recommended in future studies.
A TDC-procedure which is further similar to the one
from the present study, including using the mode of sep-
arately added reference items allows then monitoring of
late pronounced signs and symptoms during treatment,
and will yield objective data on the number of visits
needed for treatment and treatment duration. The data
on visits and treatment duration would even be free
from any possible clinician-bound bias if it is possible or
feasible that the data for evaluation at the various visits
of treatment are obtained by a non-clinician (it remains
then essential to consider the treatment period as a
black box regarding the post-treatment TDC-values).
Based on the TDC-data from a blinded assessor, a
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ing the use of initially zero Contrast-values, will yield
nearly unbiased data on success rate and efficacy of
treatment.
In the present study, scores were used that have a zero
value when there is no pain or impairment and a maximal
value when the extent of pain or impairment is greatest.
The Appendix (section ‘The use of TDC on scales with a
reversed meaning’), outlines how to handle scales with a
reversed meaning. Furthermore, the Appendix (section
‘The use of TDC when a priori knowledge of an item’s un-
impaired value is lacking’) outlines how to use TDC when
the value of a score corresponding to ‘least impairment’ is
a priori unknown for a patient.
Differences between TDC and ROM procedures
ATDC-procedure differs in three aspects from a traditional
Routine Outcome Monitoring (ROM). First, in the TDC-
procedure, items with sufficiently large score values either
at baseline or during treatment are selected as reference
items for monitoring relative change. Thus relative change
is tested adaptively only for those signs and symptoms
which are statistically pronounced and are of interest for
the clinician to follow. By contrast, all items of a multidi-
mensional questionnaire are included in a traditional ROM
using raw change. Apart from a possible difference in sensi-
tivity to detect change between a TDC-procedure and
ROM, the outcome value of ROM might be more ambigu-
ous than that of a TDC-procedure. If large score values of
items would wane during treatment and would be replaced
by large scores values of other items, such an event will not
be reflected in the summed or averaged outcome variable
of ROM. A ROM outcome at a particular visit only reflects
a mean actual state. In a TDC-procedure, the detection of
items with sufficiently pronounced scores is always con-
comitant with the attribution of a reference score value
which is used to determine a Contrast-value. Once an item
has been detected as a reference item, its Contrast-values
contribute to the TDC-values of subsequent visits. Thus
TDC has a ‘memory’ which requires (as explained above)
to consider the treatment period as a black box for obtaining
unbiased outcome variables in a Randomized Controlled
Trial with variable treatment duration.
Second, the TDC-procedure differs from the traditional
Routine Outcome Monitoring (ROM) in the end level of
the scores and also likely in treatment duration. Using
TDC, the smaller a patient’s baseline is, the end scores fol-
lowing successful treatment will be closer to zero, hence
more remote from the Upper Limit of Functional Status
(ULFS; Figure 1). In order to decide that a treatment is
successful, two criteria are used in a traditional ROM, i.e.
(1) a decrease in averaged score values from a question-
naire should exceed the Smallest Detectable Difference
(SDD) for such averaged scores, and (2) the end level ofthe averaged scores should have passed ULFS. In Contrast
to the TDC-procedure, the end levels will therefore tend
to be closer to ULFS in ROM. Treatments of patients
whose baseline is located just above the ULFS at a small
distance of SDD for a score average, and whose end score
drops just below ULFS, will then be considered as being
successful. If such a high end level occurred in chronic
pain patients by using a ROM based on raw change while
the perception of improvement by treatment is associated
with relative change [15], there might occur a discrepancy
between a favourable ROM outcome and a patient’s per-
ception of only a small improvement (cf. Background).
Such a discrepancy might increase the risk on relapse.
End levels as controlled by TDC that are proportional to
the baseline concur with a relationship between relative
decrease in pain intensity and the patient’s assessment of
treatment effect that is independent from the baseline in
chronic pain patients [15]. If treatment success is associ-
ated with the patient’s assessment of treatment effect of,
for example, ‘much improved’ or better, then this assess-
ment is related to a particular relative decrease in pain in-
tensity. Such a decrease, applied as a multiplication factor
to a patient’s baseline of pain intensity will yield an end
level of pain intensity that is proportional to the baseline
(Figure 1). Further research is required to examine the ex-
tent to which a relationship between relative decrease in
signs and symptoms and assessment of treatment effect
occurs in general in diseases and disorders and whether
the risk on relapse will be smaller with TDC than with
procedures using raw change.
A third difference between the TDC-procedure and
a traditional ROM concerns regression to the mean.
Whereas bias by regression to the mean does not occur
with TDC-values as explained before, a raw change in
score level, for example the change in score of pain inten-
sity, will always show some regression to the mean of pain
intensity or to the mean of any other variable that is re-
lated to severity of the disorder. ROMs using raw changes
in score levels are thus susceptible to this artefact by
which treatment effect might be somewhat overestimated,
in particular when the threshold of signs and symptoms is
chosen relatively high at the intake of the patients.
Validation
The criterion of TDC ≤ −0.379 (in combination with the
occasional use of the discrepancy rule) for distinguishing
between a successful/unsuccessful treatment, has proven
to be reliable on five grounds.
First, the distribution of the TDC-values is bimodal in
the long-term, representing two groups of patients in re-
spect of their treatment outcomes. The separation be-
tween the two groups might have been better still had a
slightly more negative cut-off point been used, notably
TDC ≤ −0.560 instead of ≤ −0.379 (Figures 3B, C-D).
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reinforced by another finding from the present study. The
distribution of post-treatment scores of patients from the
current large sample, whose treatment is successful, sug-
gests that the level of the Upper Limit of Functional Status
(ULFS) might be 1.08 units rather than 1.40 units as
assessed by a panel using scores from a pilot sample (see
Appendix, section ‘Choosing two cut-off points of TDC’).
Such a lower level of ULFS would correspond to a more
negative cut-off point TDC = −0.482 instead of −0.379. A
limitation of the present study is that normative score
values from Community Control subjects (CoCos) are
lacking for the various items. Data from CoCos might im-
prove the assessment of the ULFS and hence the deter-
mination of the cut-off value of TDC.
However, the use of a slightly less conservative cut-
off value TDC = −0.379 in combination with the dis-
crepancy rule in which the patient’s demand for sub-
sequent treatment can overrule the conclusions of the
clinical examination, is actually more effective than a
more negative TDC-value as cut-off. If the criterion
TDC ≤ −0.379 alone were used, 4 patients out of 118
(3.4%, Figure 3B) would have been classified as being
successfully treated despite the fact that these patients
disagreed with this conclusion. This disagreement was
solved by application of the discrepancy rule. Using a
more negative TDC-value (−0.560), 2 of these 4 pa-
tients would have been correctly classified as having
had unsuccessful treatments. Three other patients,
however, would then have been classified as being un-
successfully treated whereas these patients had no de-
mand for further treatment. Thus the use of a less
conservative cut-off TDC-value in combination with the
discrepancy rule has prevented over-treatment of these
three patients.
The finding that TDC-anamnestic (patient assessing
daily functioning) indicates less improvement than TDC-
clinical from the clinician, supports the use of the discrep-
ancy rule. TDC-anamnestic remained constant from the
end of treatment while TDC-clinical increased when an-
other person than the clinician carried out clinical testing.
The more favourable clinician’s value for TDC-clinical
might, apart from a clinician-bound bias, be related to a
patient’s tolerance to clinical testing that develops during
treatment and is clinician-bound.
A second ground of validity is that the VAS-scores of
pain intensity become residual in the long-term in pa-
tients whose treatments were successful according the
TDC-criterion (Figure 4). Thus 55.1% of the VAS-scores
is ultimately zero, and even the maximal value (35 mm)
is smaller than the long-term SDD of VAS-scoring
(49 mm [18]). Being a reference item of TDC, this de-
crease in VAS-score has occurred with a simultaneous
decrease in score values of other items.A third ground of validity is that the increased utility
values of EQ-5D (a variable that is independent from
TDC) in patients whose treatment is successful (mean
0.917 units), corresponds to a self-rated global health of a
general population sample that is ‘good’ to ‘very good’ [28].
A fourth reason for validity would have been provided
in a direct manner by an association between relative de-
crease in the score of pain intensity and the assessment of
treatment effect by the various myogenous TMD patients.
However, a limitation of the present study is that assess-
ment scorings are lacking. A second-best solution is con-
sidering the association between mean percentage
decrease in score of pain intensity and the assessment of
treatment effect by chronic pain patients, regardless of
their baseline of pain intensity (Figure eight in reference
[15]). The mean decrease of 90% that occurred in the
TMD patients with a successful treatment according to
the TDC-criterion, is related to ‘very much improved’ or
better in the perspective of chronic pain patients. A de-
crease of 55% in pain intensity that corresponds to the
cut-off point TDC= −0.379 is related to ‘much improved’
or better. The cut-off point TDC = −0.212 (decrease of
35% in pain intensity) used to distinguish between suffi-
cient/insufficient responsiveness is related to ‘moderately
improved’ (between the categories ‘minimally improved’
and ‘much improved’).
A decrease of 55% in pain intensity that corresponds to
the cut-off point TDC = −0.379 corresponds also closely
to the expectation of patients with facial pain or fibro-
myalgia regarding treatment of their symptoms [14]. The
expected reduction of pain, fatigue, distress or interference
with daily activities varied within a small range from 56%
to 63%, regardless of the type of chronic pain patient.
A fifth ground of validity is that the success rate of treat-
ment in the present study (75% in the short-term) is simi-
lar to that (75-80%) reported in TMD textbooks [29-31].
Application
The purpose of TDC is to allow a clinician to make deci-
sions on the progress and ending of a treatment in a
standardized way that complies with clinical care to en-
able randomized controlled trials under natural condi-
tions. As TDC enables an objective determination of
treatment duration and the number of visits required in
individuals, TDC will facilitate a costs-effectiveness-ana-
lysis of therapies. Like in a traditional Randomized Con-
trolled Trial, stringent inclusion and exclusion criteria
were applied to select the patient sample of the present
study [Appendix, ‘Inclusion and exclusion criteria of the
patients’, [17]. In particular, patients were excluded who
had any previous TMD treatment (either a dental one or
physiotherapy), or other treatments for pain (also
nonfacial pain) more recent than a year. However,
the TDC-procedure enables to determine treatment
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usual patient intake of clinical care.
Apart from patients suffering from chronic pain and ten-
derness of the muscles of mastication, the TDC-procedure
is potentially suitable for monitoring other disorders or dis-
eases in which, as for chronic pain patients in general, the
patients’ assessment of treatment effect is related to relative
decrease in signs and symptoms, regardless of the baseline.
A TDC-procedure might be of interest for psoriasis, a sys-
temic chronic-inflammatory disorder affecting predomin-
antly the skin. A primary outcome uses relative decrease in
the Psoriasis Area and Severity Index (PASI) [32,33]. Cor-
relations between decrease in PASI and the Dermatology
Life Quality Index (DLQI) or a VAS-score of the patient’s
assessment of psoriasis activity respectively are enhanced
by considering relative change [34].
Using scores of key items from appropriate instruments,
definition is only required of (i) a disorder-specific upper
limit of functional status, and (ii) a disorder-specific cut-off
point of TDC, which is related to a constant factor of rela-
tive change needed to pass this upper limit in patients with
the largest levels of severity in the sample so that the cut-
off point of TDC will be applicable to any patient. The
upper limit of functional status is at a low level for
myogenous TMD confining a zone of functional status of
healthy people. This limit will probably be at a higher level
for a degenerative disease or disorder because of a lack of
potential of therapy to diminish signs and symptoms com-
pletely. For a patient with maximal scores, the degree of
relative change required to attain a higher upper level of
functional status will then be smaller than for myogenous
TMD. Hence the cut-off value of TDC will then be larger
(less negative) than −0.379.
Apart from the use as an index with a cut-off point to
control treatment duration, this cut-off point of TDC is
further used to classify treatment outcome dichotomously
as being successful/unsuccessful, using data from a blinded
assessor. Success rate between therapies can then be differ-
entiated using non-parametric chi-square statistics.
Traditional single outcome variables may still be useful
in powerful parametric statistical tests on unpaired obser-
vations to detect differences in efficacy between therapies,
using mean and SD values. Post-treatment TDC-values
might be less suitable for such tests as TDC is obtained by
averaging Contrast-values with patient-specific numbers.
The variance of TDC-values will therefore differ between
patients. Traditional multi-dimensional scales in which raw
score values are summed or averaged (used in traditional
Routine Outcome Measurement) might have a similar
variance problem as the scorings from all items contribute
to the overall outcome value, including those items for
which impairment is lacking. Patients with relatively small
signs and symptoms might have a small overall outcome
value with a small variance because of a large contributionof zero score values for which variance is lacking. Avoiding
this floor effect by raising the intake threshold of the pa-
tients’ signs and symptoms will, in a traditional ROM but
not in a TDC-procedure, increase the risk on confounding
the treatment outcome with effects of regression to the
mean. The variance problem might be accounted for by
stratifying patients across samples according to number of
contributing items and/or the use of a non-parametric
Kruskal-Wallis test.
Conclusions
TDC allows a clinician to decide on the end point of treat-
ment in a way that attaining functional status by a suffi-
ciently large relative improvement in score levels will be
concomitant with a perception of a substantial treatment
effect by chronic pain patients. In combination with eva-
luation by a blinded assessor, TDC enables randomized
controlled trials with therapies that have a variable
therapy- and patient-specific duration.
Appendix
Averaging of ratio values between scores from two times
of measurement
Three possible methods of averaging ratio values between
subsequent score values are: (1) calculating the ratio be-
tween the mean score values at the second time of meas-
urement and the mean baseline scores, (2) determining the
mean of the ratio values of the pairs of successive score
values from various items, and (3) determining the mean of
the ratio values under (2) that have first been transformed
to attain a zero point to which values of an equivalent rela-
tive increase and decrease have the same distance.
In order to illustrate the three methods of averaging,
Table 6 shows numerical examples of three items at two
times, i.e. scores S1,i and S2,i (in which i is the item num-
ber, i = 1 .. 3), with three values of the ratio between S2,i
and S1,i which correspond with three multiplication fac-
tors to describe the transition from S1,i to S2,i. The
multiplication factors chosen are 2 (increase by a factor
of 2), 1 (no change) or 0.5 (decrease by a factor of 2).
Three situations are shown: (i) equal values of the three
items at baseline (S1,i-values, Table 6, top), (ii) a smaller,
intermediate and a larger S1,i-value which are subjected
to multiplication by 2, 1 and 0.5 respectively (middle), or
(iii) to multiplication by 0.5, 1 and 2 respectively (bottom).
Table 6 also gives the mean S1,i- and S2,i-scores and the ra-
tio between both mean values (Method (1)), and the mean
of the multiplication factors (mean of Ri values, Method
(2)). Furthermore, Table 6 shows logarithmical trans-
formed values of the multiplication factors (log(Ri)) and
the mean of these transformed values (Method (3)). The
multiplication factors have also been transformed to
Contrast-values (Ci = (Ri - 1)/(Ri + 1)), and the mean of the
Contrast-values is shown (second variant of Method (3)).
Table 6 Three possible methods of averaging ratios between successive score values
equal baseline scores:
S1,i ratio (Ri) S2,i log(Ri) Ci = (Ri-1)/(Ri + 1)
50 2 100 0.301 0.333
50 1 50 0.000 0.000
50 0.5 25 0.301 -0.333
Method (1): mean S1,i = 50.0 Method (2): mean of Ri values: 1.17
mean S2,i = 58.3
(mean S2,i)/(mean S1,i) = 1.17
Method (3): mean of log(Ri) values: 0.000 ; mean R: 1.00
(re-transformed mean log-value:10(mean log(Ri))
mean of Ci values: 0.000 ; mean R: 1.00
(re-transformed mean C-value: (1 + C)/(1-C))
non-equal baseline scores, largest baseline with smallest Ri value:
S1,i ratio (Ri) S2,i log(Ri) Ci = (Ri-1)/(Ri + 1)
20 2 40 0.301 0.333
40 1 40 0.000 0.000
60 0.5 30 -0.301 -0.333
Method (1): mean S1,i = 40.0 Method (2): mean of Ri values: 1.17
mean S2,i = 36.7
(mean S2,i)/(mean S1,i) = 0.917
Method (3): mean of log(Ri) values: 0.000 ; mean R: 1.00
(re-transformed mean log-value:10(mean log(Ri))
mean of Ci values: 0.000 ; mean R: 1.00
(re-transformed mean C-value: (1 + C)/(1-C))
non-equal baseline scores, largest baseline with largest Ri value:
S1,i ratio (Ri) S2,i log(Ri) Ci = (Ri-1)/(Ri + 1)
20 0.5 10 0.301 0.333
40 1 40 0.000 0.000
60 2 120 -0.301 -0.333
Method (1): mean S1,i = 40.0 Method (2): mean of Ri values: 1.17
mean S2,i = 56.7
(mean S2,i)/(mean S1,i) = 1.42
Method (3): mean of log(Ri) values: 0.000 ; mean R: 1.00
(re-transformed mean log-value:10(mean log(Ri))
mean of Ci values: 0.000 ; mean R: 1.00
(re-transformed mean C-value: (1 + C)/(1-C))
S1,i and S2,i, subsequent score values of three items ( i = 1..3) at times ‘1’ and ‘2’ respectively. Ri, ratio between S2,i and S1,i (multiplication factor of S1,i). log(Ri),
logarithmically transformed Ri-values. Ci, Ri-values transformed as Contrast-values. Three methods of averaging ratio values are illlustrated; Methods (3) includes
two variants of data transformation, logarithmically and as Contrast. For further explanation, see text.
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tio between the mean S2,i-value and the mean S1,i-value
(Method (1)) equals the mean of the multiplication
values, Ri (Method (2)). When the values of S1,i differ,
the outcome of the ratio between the mean S2,i values
and the mean S1,i values largely depends on how the lar-
gest S1,i value is modulated. If this value is multiplied by
a factor 0.5 (a decrease, Table 6, middle), this ratio issmaller than the mean of the multiplication factors. Re-
versely, if the largest S1,i value is multiplied by the factor
2 (an increase, Table 6, bottom), the ratio between the
mean S2,i-values and the mean S1,i-values is larger than
the mean of the multiplication factors. The mean value
of the logarithmically transformed factor values is zero
because the transformed values of an equivalent
decrease and increase by a factor of 2 have the same
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The multiplication factor 1 which reflects no change be-
comes also zero as a log-value. When multiplication fac-
tors are transformed to Contrast-values, there is, like for
log-values, also a zero point to which an equivalent
relative increase and decrease have the same distance.
Thus the mean of the transformed factors underlying
these changes is zero.
Thus Method (1) of averaging ratios (determining the
ratio between mean S2,i and mean S1,i) is dominated by
the change in the score which has the largest baseline
value. Method (1) is also arbitrary as weighing factors are
unknown by which scores from different items might be
summed and subsequently averaged adequately. The sec-
ond and the third method are invariant to the baseline
levels of the scores as only the ratio values from the vari-
ous pairs of successive scores are considered. However,
the second method (mean of ratio values) might yield an
inappropriate outcome regarding the overall tendency of
the multiplication factors. For example, when the score of
a first item shows an increase by a multiplication factor of
2 and a second item shows a decrease by a factor of 2
(multiplication factor 0.5), the mean of the values 2 and
0.5 equals 1.25. This outcome indicates an overall factor
of relative increase for the various pairs of subsequent
scores as a mean of 1.25 is larger than a mean factor of 1
that represents no relative change. The reason for this in-
adequate outcome is that the values of 2 and 0.5, corre-
sponding with an equivalent relative increase and
decrease in score value, do not have the same distance
to the zero point of ratio values. When the ratio values
2 and 0.5 are first transformed (method (3)), for ex-
ample logarithmically, the mean of the log-values of 2
and 0.5 (+0.303 and −0.303) becomes zero. In general,
when a score increases by a factor k while a score from
another item decreases by the same factor k (multiplica-
tion by 1/k), the logarithmic values of the multiplication
factors k and 1/k are equidistant with respect to the zero
log-value as log(k) = −log(1/k).
Thus ratio values have been transformed in the
present study to attain an index of averaged transformed
multiplication factors of which the value zero reflects an
overall factor related to no change. When the mean log-
value which is zero in the abovementioned examples, is
transformed back, the value of the overall multiplication
factor is 1, representing no relative change indeed. A
positive mean of transformed factor-values and a nega-
tive mean value are related to an overall relative increase
and decrease respectively in the ratios (multiplication
factors) between various pairs of subsequent score levels,
regardless of the score levels themselves. A positive
mean of transformed score values corresponds to an in-
crease in pain or impairment, whereas a negative mean
corresponds to a decrease.However, the logarithmic ratio value from two succes-
sive scores within a patient (log(Ri) = log(S2,i/ S1,i), in
which S2,i is the second score of item i, and Ri the ratio
between both scores) will be undefined (infinite nega-
tive) when S2,i becomes zero after a complete disappear-
ance of pain or impairment. In order to avoid undefined
values, a Contrast (C) value between inter-visit scores
was determined for each item that contributed to the
average. The value of Ci, a normalized difference value
between two measurements of item i, was given by:
Ci ¼ S2;i−S1;i
 
= S2;i þ S1;i
 
; ð1Þ
in which S1,i is the reference score of the i-th item and
S2,i the score at a later visit.
The possible values of Ci vary within a range from −1
to +1. Ci is related to the relative change in score values.
Equation (1) can be rewritten as Ci = (Ri - 1)/(Ri + 1) in
which Ri is the ratio between S2,i and S1,i. Like for loga-
rithmically transformed values, an increase of a score by
a factor k is equivalent to a decrease by this factor k
when scores are transformed to C-values as, apart from
the sign, both C-values are equidistant to the zero-point.
(see Table 6 for a numerical example with a factor of 2).
Thus with an increase of the reference score by a factor
k, C = (k - 1)/(k + 1), according to equation (1), and with
a decrease by a factor k (multiplication by 1/k), C’ =
(1-k)/(1 + k) = −C.
Ci values and logarithmic ratio values between S2,i and
S1,i are numerically similar within a wide range of logarith-
mic ratio values on both sides of the zero point (Figure 6).
As a numerical example of Ci: before treatment, a patient
scored a pain level of ‘4’ after palpation of the left superfi-
cial masseter muscle. Since the score became ‘2’ at a later
visit, Ci of this item was −0.333 (= (2–4)/2 + 4) = −2/6). Ci,
in this example −0.333, is similar to the logarithmic value
of the ratio between both scores, log(2/4) = −0.301.
At the various treatment visits, actual score values
from a later visit were compared with respect to the ref-
erence values. Only those items were considered that
were related to sufficiently pronounced signs or symp-
toms (reference items).
For each reference item i, the Contrast-value Ci was
determined according to equation (1). For each treat-
ment or follow-up visit of a patient, all Ci values were
averaged to obtain a single summarizing index, ‘Treat-







in which n is the number of items.
TDC is related to an overall ratio (multiplication fac-
tor) between various pairs of subsequent score levels
Figure 6 Contrast-value as a function of logarithmic value of
the ratio between two score values (solid curve). Ratio R = S2/S1,
in which S1 and S2 are the first and the second score value. When
there is no difference between S2 and S1, both the Contrast-value
and the value of log(R) are zero (hatched lines). When S2 is zero and
S1 has a positive value, log(R) is undefined (infinite negative)
whereas the Contrast-value is −1.0. When S2 has a positive value
while S1 is zero, log(R) becomes undefined (infinite positive) whereas
the Contrast-value is +1.0. If all Contrast-values were numerically
identical to log(R) values, the relationship between Contrast and log
(R) values would be depicted by he dotted straight line. Note that
although not identical in general, Contrast and log(R) values are
numerically similar (deviation with respect to the mean of both
types of values < 15%) for a wide range of log(R) values on both
sides of the zero point (range −0.80 to +0.80).
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score levels themselves. The name of the index ‘Treat-
ment Duration Control’ refers to the use of cut-off
values of TDC for controlling treatment duration.
For Contrast-values which are sufficiently remote
from the extreme values of −1 or +1 (−0.8 < Ci < 0.8),
each term Ci in equation (2) is approximated well by log







thus TDC is then approximately the logarithmic value of






) between the various pairs of
subsequent score values. The geometric mean of the ra-
tios (the global multiplication factor related to TDC)
corresponds approximately to the median of the ratios if
the log transformed ratios have a (roughly) symmetrical
distribution.
One might argue that percentage change might be used
as a measure of relative change rather than Contrast. A
percentage increase is, however, apart from the sign not
equivalent to the same percentage decrease in terms of
multiplication factors. As a numerical example, 20% in-
crease of a score S1 of 100 arbitrary units means that S2will be 120 units. Thus the transition of S1 to S2 can be de-
scribed by multiplying S1 by a factor of 1.2 (120/100). A de-
crease of 20% means that S1 of 100 units becomes S2 of 80
units. This transition can be described by S1 multiplied by
a factor of 0.8. The reversed value of this factor equals 1.25
(1/0.8) which is unequal to the multiplication factor of 1.2
describing an increase of 20%. A transformation of ratio
values between successive score-values to Contrast-values
remains most appropriate to average values of relative
change across various reference items.
Lack of bias by regression to the mean in Contrast and
TDC-values
In order to avoid random fluctuations in TDC-values,
items with a sufficiently large starting value S1,i have been
selected as ‘reference items’. One might argue that such a
selection might introduce the risk on regression to the
mean and might cause bias in the treatment outcome.
Such a mechanism by chance is, in part, involved in a de-
crease in a raw score value following treatment, which has
initially a large value (by merely having a large initial value
such a score has a larger chance to decrease than to in-
crease, irrespective of any treatment effect). A significant
linear regression with a negative gradient occurred in the
relationship between the raw differences in a later score
and the baseline one and the baseline scores from the vari-
ous patients. For example, the difference in VAS score of
predominant pain between the last measurement
following treatment (score S2) and baseline (score S1)
decreased on average according to the regression function:
(S2 - S1) = −0.709.S1 + 4.337, with a Pearson’s correlation
coefficient of 0.601 (n = 118). In combination with a pos-
sible treatment effect, this significant (p < 0.001) regression
is thus, in part, due to regression to the mean by chance.
Ignoring the scatter in the post-treatment scores (S2)
for the moment, a relationship between difference in
scores and the corresponding baseline score (S1) can be
described by:
S2  S1
  ¼ a:S1 þ b; ð3Þ
in which a is the gradient, b the intercept, and S2  S1
 
is the mean difference between S2 and S1 that occurs
with S1 according to the regression function. In this
mean difference, S1 is a value from an individual patient
whereas the corresponding value of S2 is a mean value
which is further denoted as S2 .
From equation (3) it follows that the ratio between S2
and S1 is given by:
S2=S1 ¼ aþ 1ð Þ þ b ¼ c; ð4Þ
in which c is a constant. Thus the ratio between the
mean value S2 and the corresponding baseline score S1
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sponding value of S1. The logarithmic value of the ratio
is also constant:
log S2=S1ð Þ ¼ log cð Þ ¼ c’ ð5Þ
Contrast-values between S2 and S1 which are suffi-
ciently remote from the extreme values of −1 or +1
(−0.8 < Ci < 0.8), approximates the logarithmic ratio
value (see Appendix section above), hence:
S2−S1ð Þ= S2 þ 1ð Þ≈log S2ð Þ=S1 ¼ c’ ð6Þ
Thus the Contrast-values are also independent from
their corresponding values of S1.
In the abovementioned relationship between pre- and
post-treatment VAS scores of predominant pain inten-
sity on a 100 mm scale, scatter is involved in the S2-
values. While the relationship between the difference in
score values (S2 - S1) and the corresponding baseline
score (S1) yielded the regression function:
(S2 - S1) = −0.709.S1 + 4.337 (r = 0.601, n = 118, p <
0.001), the relationship between the ratio S2/ S1 and S1
of the VAS-scores was described by the regression
function:
S2/ S1 = −0.00592. S1 + 0.709 (r = 0.171, n = 118, not sig-
nificant). The gradient of this relationship was less steep
than the gradient of the relationship between (S2 - S1) and
S1 (equation (3)), and the regression was non-significant,
which could be expected according to equation (4). How-
ever, the scatter of the ratio values (S2/S1) became smaller
the larger the S1 values, and was large for small S1 values
in particular.
The relationship between the Contrast-values [(S2 - S1)
/(S2 + S1)] and S1 was described by the regression
function:
(S2 - S1)/(S2 + S1) = −0.000829.S1 – 0.540 (r = 0.0387,
n = 118, not significant). The regression line of this rela-
tionship was nearly horizontal. Furthermore, the band of
scatter of the Contrast-values was similar within the entire
range of S1 values, because (in contrast to ratio values) the
distribution of Contrast-values is symmetrical. Further-
more, Contrast-values are limited between −1 and +1, thus
large deviations from the regression line were avoided.
The constant bandwidth of scatter of the Contrast-values
around the nearly horizontal regression line (which ap-
proximates the mean of the Contrast-values) means that,
following treatment, a similar variety of relative change in
pain intensity occurs in different patients, regardless of the
baseline level of pain intensity. Thus by transforming dif-
ference values to Contrast-values (normalized difference
values) any regression, also one to the mean which oc-
curred in the difference values as a function of the baseline
values, is eliminated.A regression in the relationship between Contrast-value
and baseline value of the item will be lacking for any item
according to equation (6), with a constant bandwidth of
scatter because of the use of Contrast-values. Thus the
index TDC being the mean of Contrast-values from sev-
eral items (equation (2)) includes components that are all
invariant to each of their baseline values. For each patient
only those items were included in TDC that were related
to sufficiently pronounced signs or symptoms of that pa-
tient (reference items). The baseline of each of these se-
lected items is therefore related to the patient’s baseline of
severity of myogenous TMD, and all the patient’s
Contrast-values are invariant to the baselines of the corre-
sponding items as well as to this baseline severity. A re-
gression will therefore be lacking in the relationship
between TDC and the baseline of an item which can be
used to characterize the baseline severity of myogenous
TMD of the various patients in the sample. Such charac-
terizing items are the predominant pain of the masticatory
system (VAS-scores) and to some extent generic Health-
related Quality of Life (EQ-5D utility units). A lack of re-
gression has been observed indeed, between TDC and
pain intensity and HRQoL respectively (Figures 4A-B).
The constant bandwidth of scatter of post-treatment
TDC-values around the nearly horizontal regression line
means that, a similar variety of TDC-values from different
patients occurs, regardless of the severity level of
myogenous TMD. Patients whose TDC-value has dropped
to or beyond the cut-off level of −0.379, only have attained
functional status. With a constant bandwidth of scatter,
the fraction of patient whose TDC ≤ −0.379 is constant
and the chance of attaining functional status is therefore
independent from the baseline severity level of myogenous
TMD of the patient.
Scores from anamnesis and clinical examination
The anamnestic questionnaire included scoring on adjec-
tival 0–4 point scales (Table 1) of frequency of pain from
the masticatory system, stiffness or fatigue of the jaw mus-
cles and limitations to movement of the jaw. Furthermore,
the extent of impairment of chewing hard food and yawn-
ing respectively was scored. The questionnaire also in-
cluded scoring of the intensity of the predominant pain
from the masticatory system on a 100 mm Visual
Analogue Scale (VAS; anchor points: ‘no pain’ and ‘the
most intense pain one can imagine’). The total number of
anamnestic items related to myogenous TMD, was 6 of
which 5 were scored on 0–4 point scales.
The clinical examination included scoring of pain inten-
sity on a adjectival 0–4 point scale during: (i) active and
passive jaw movements in vertical, lateral and anterior-
posterior directions, (ii) palpation of the deep and superfi-
cial masseter muscles, the anterior and posterior tempor-
alis muscles, the sternocleidomastoid and the attachment
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patient had been instructed to clench in eccentric posi-
tions as well as in maximal occlusion. As pain was scored
for both sides and palpation and most jaw movements
were also side-related, the total number of clinical items
was 42.
Choosing two cut-off points of TDC
Two cut-off points of TDC are necessary to control
treatment duration. A first cut-off point was used to de-
cide whether a patient had responded sufficiently follow-
ing a treatment-specific time interval. A second cut-off
point served to decide when the upper limit of func-
tional status had passed and the treatment had become
potentially ‘successful’.
Regarding the first cut-off point of TDC: for a treatment
which has a moderate effect at most, the majority of the
end scores will be ‘2’ or ‘3’ in patients where an initial level
of ‘3’ or ‘4’ predominated on an adjectival 0–4 scale of ex-
tent or frequency of pain or impaired function. The end
situation corresponds to a patient’s condition in which
‘moderate/regularly’ pain and/or impaired function occurs.
TDC = 0.212 was chosen as the first cut-off point to de-
scribe approximately the mean of Contrast-values of the
transitions in score values from ‘4’ to ‘3’ (Contrast: -0.143 =
(3 – 4)/(3 + 4)), ‘4’ to ‘2’ (C: -0.333), and ‘3’ to ‘2’ (C: -0.200).
The cut-off point TDC = −0.212 corresponds to a decrease
of 35% in a single score of pain intensity at a 100 mm
VAS [−0.212 = (65 – 100)/(65 + 100)]. If a patient’s TDC
was larger than −0.212 (TDC > −0.212) at a critical stage
of treatment, the patient was insufficiently responsive (a
less negative value than −0.212 means less change towards
recovery).
Regarding the second cut-off point of TDC, the upper
limit of functional status (ULFS) must first be determined.
Functional status in myogenous Temporomandibular Dis-
orders is characterized by a low level of signs and symp-
toms that might occasionally occur in healthy subjects.
Normative data of the items from Community Control
(CoCo) subjects were lacking Thus ULFS could not be
assessed by determining the 95th percentile of score
values from CoCos following the same anamnestic and
clinical examination as used for the TMD patients. How-
ever ULFS could be approximated in the following way. In
the adjectival 0–4 point scales used in the present study,
the score ‘0’ means ‘no pain or impairment’ and the score
‘1’ means ‘slight’ pain or ‘sometimes’ painful or ‘sometimes’
impairment and the score ‘2’ means ‘moderate’ pain, ‘regu-
larly’ painful or ‘regularly’ impairment (Table 1). A panel of
five dentists specialized in TMD agreed that a functional
status is characterized by a large majority of scores with
end values of less than 2 units. After considering the post-
treatment score values of 20 patients from a pilot sample, a
mean score level of 1.40 units was assessed for ULFS.The following procedure was followed to select a patient
from the pilot sample, with overall maximal signs and
symptoms of myogenous TMD, and to determine the cut-
off value of TDC related to the factor T required to attain
ULFS from baseline. Score values from 0–4 point scales
were available for 5 anamnestic items and 42 clinical
items. Items with sufficiently large score values at baseline
(i.e. a score value of 2, 3 or 4, which exceeded the smallest
detectable difference (SDD; see the main text for more de-
tails) were selected for each patient as reference items for
calculating Contrasts and the TDC-value. The patients
could be ranked according to their overall level of signs
and symptoms by considering the summed score value of
the reference items at baseline as a primary ranking criter-
ion and the number of reference items as a secondary cri-
terion. The patient with maximal signs and symptoms had
a summed score value of 104 to which 32 items contrib-
uted, i.e. 7 scores with a value ‘2’, 10 scores of ‘3’, and 15
scores of ‘4’ . The Contrast between a score value of 2
and the level of ULFS (1.40 units) is −0.176 (= (1.4 - 2)/
(1.4 + 2)), and the Contrast-values are −0.364 and −0.481
for a baseline score value of ‘3’ and ‘4’ respectively. The
mean of all Contrast-values of the patient with the
abovementioned score profile yields the TDC-value
of −0.378 (= [−7 × 0.176 –10 × 0.364 – 15 × 0.481]/32).
This TDC-value corresponds with a value for 1/T of 0.451
(= [1 + (−0.378)]/[1 - (−0.378)]; hence a treatment factor T
of 2.22) and to a decrease of 54.9% in a single score value
of pain intensity (= (1–0.451)*100%). The value of the de-
crease in pain intensity has been rounded off to 55% and
hence the value −0.379 was chosen as a cut-off point of
TDC for deciding whether ULFS had been passed during
treatment of the patients from the present study.
In retrospect, two patients from the large sample of
118 patients from the present study, had overall a higher
level of signs and symptoms (score profiles of baseline
reference items: 1 × 2, 8 × 3, 30 × 4, and 7 × 2, 9 × 3, 17 ×
4) than the patient from the pilot sample (7 × 2, 10 × 3,
15 × 4). Their sum value was 146 and 109 and the num-
ber of reference items was 39 and 33 respectively rather
than 104 (sum value) and 32 (number of reference
items) of the patient from the pilot sample. However,
their mean score level across the reference items (94%
and 83%; 100% means a maximal score value of 4 for
all items) was not increased much with respect to
the mean of the patient from the pilot sample (81%),
because many items had a maximal score value of 4
units. The cut-off values of TDC with respect to an
ULFS value of 1.40 were therefore only slightly more
negative for the two patients from the current sam-
ple than for the patient from the pilot sample, i.e.
TDC = −0.449 (62.0% decrease in a single score of
pain intensity), TDC = −0.385 (56.1% decrease) rather
than TDC = −0.378 (54.9% decrease).
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(from the last follow-up visit) pooled across patients from
the present study whose treatment was successful in the
long-term, provided information on the Upper Limit of
Functional Status (ULFS) in retrospect.
First, the post-treatment scores of only the reference
items were considered for each patient, in total 786 scores
from 66 patients. These scores had initially a high score
level of 2, 3 or 4 units on a 0–4 point scale, reflecting pro-
nounced signs and symptoms of the patients, and, had in
general a low level following a successful treatment. The
frequency of reference items from the various patients of
the entire sample (patients with and without a successful
treatment) differed between items, i.e. it varied within a
range from 47% to 82% for items related to anamnestic
questions and from 6% to 69% for items related to clinical
examination. In order to account for these differences be-
tween items in the chance of being a reference item in
myogenous TMD patients, the number of any post-
treatment value of a reference item was weighted according
to this chance. The 95th percentile of the weighted distribu-
tion of post-treatment scores of reference items from the
patients with a successful treatment, was 1.66 units. This
upper limit of 1.66 units of residual score values is only
slightly larger than the value of 1.40 units which was a
priori attributed to ULFS by the panel, based on post-
treatment scores from the pilot sample of 20 patients (see
above). The current TDC-procedure based on an ULFS of
1.40 units was so effective that this level confined 92.5% of
the post-treatment scores of reference items in patients
whose treatment was successful according to the criterion
TDC ≤ −0.379.
Second, all post-treatment scores were considered which
were pooled across the patients whose treatment was suc-
cessful (in total 3102 scores from 66 patients). Thus apart
from reference scores, also scores which had initially small
values of 0 or 1 units were considered. In order to diminish
the influence of post-treatment score values from items
which were rarely involved as reference items (thus attenu-
ating the possible influence of many zero values from those
items which rarely detect signs and symptoms), the number
of any post-treatment value of any item was weighted again
according to the chance of this item of being a reference
item. The 95th percentile of the weighted distribution of
post-treatment scores of all items was 1.08 units. As this
distribution might approach the one from Community
Controls, this finding suggests that the actual value of
ULFS might be somewhat smaller than 1.40 units for
myogenous TMD. A smaller value of ULFS means a more
negative cut-off value for TDC for enabling the score level
of a patient with maximal signs and symptoms to attain
ULFS following treatment. Using the pre-treatment scores
of the patient with maximal signs and symptoms in the
pilot sample, the cut-off value of TDC is −0.486 (65.5%decrease in a single score of pain intensity) with a value of
1.08 units for ULFS, rather than −0.378 (54.9% decrease)
with an ULFS value of 1.40 units.
The conclusion of a more negative cut-off for TDC is
reinforced by another finding from the present study,
i.e. that the post-treatment distribution of the TDC-values
became bimodal in the long-term, representing two groups
of patients in respect of a successful/unsuccessful treatment
(Figures 3B, C and D). The finding of a slightly more nega-
tive TDC-values of −0.420 to −0.560 at the trough of the
distribution (corresponding to 59% and 72% decrease re-
spectively in a single score of pain intensity) than TDC
= −0.379 (decrease 55%) suggests that the separation be-
tween the two groups might have been better still, had a
slightly more negative cut-off point been used.
However, the criterion of TDC ≤ −0.379 has been used in
combination with a discrepancy rule in which occasionally
the patient’s demand for subsequent treatment overruled
the conclusions of the clinical examination. The patient’s
opinion as reflected in anamnestic items on daily function-
ing of the oral system was given priority in treatment out-
come if the index of overall relative change (including
changes related to items from clinical tests) indicated a ‘suc-
cessful’ treatment while the anamnestic items alone indi-
cated an ‘unsuccessful’ treatment (for details, see the main
text). The use of a slightly less conservative criterion TDC ≤
−0.379 in combination with the discrepancy rule was
actually more effective than a more negative TDC-value as
cut-off. Apart from a few patients who profoundly
expressed a demand for subsequent treatment in their
scores of anamnestic items and could overrule the conclu-
sions of the clinical examination, over-treatment of a few
other patients was prevented (cf. Discussion).
Inclusion and exclusion criteria of the patients
The patients with myogenous TMD, a chronic pain dis-
order, met the following inclusion and exclusion criteria
(cf. ref. [17]): (i) pain and tenderness of the muscles of
mastication and restricted mandibular opening of 3 month
duration or longer, (ii) no clinical and/or radiographic evi-
dence of organic TMJ changes, (iii) no previous TMD
treatment or recent (< 1 year) other pain treatment, (iv)
no evidence of serious psychopathology (no psychother-
apy and/or psycho-medication, no recent dramatic life
events), and (v) between 18 and 65 years of age. The mean
age of the patients was 31.6 years (SD 10.0); 93% were fe-
male. The median duration of pre-treatment pain was
1.1 years (range 3 months to 20 years).
The use of TDC on scales with a reversed meaning
In the present study, Contrast-values have been deter-
mined for scores of items that have always a zero value
when there is no pain or impairment and a maximal value
when the extent of pain or impairment would be the
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a decrease in score value. However, scores from other
scales than used in the present study might have a re-
versed meaning. For example, the better an aspect of qual-
ity of life, the larger a score value will be in Euroqol [35].
In order to have a consistent meaning of lacking any im-
pairment for a Contrast-value that equals −1, a score value
related to quality of life could be transformed to a comple-
mentary value by calculating the difference between the
maximum value of the scale and the actual score value.
Thus, the transformed values for the first and the second
score value are given by S1,i’ = Smax-S1,i and S2,i’ = Smax-S2,i
respectively, and the Contrast-value (Ci) of item i is given
by Ci = (S2,i’-S1,i’)/(S2,i’ + S1,i’).
For example, in Euroqol [35], the self-perceived health
status is recorded on a vertical Visual Analogue Scale of
100 units with an anchor point at the bottom of “worst
imaginable status of health” and with an anchor point at
the top of “best imaginable status of health” (EQ-5Dvas).
Suppose that the patient’s score values are 40 units (S1,i)
before and 80 units after treatment (S2,i). With a max-
imum score value of 100 units, the complimentary values
related to ‘extent of impairment of status of health’ are
then S1,i’ = 60 (= 100 – 40) and S2,I ’ = 20 (= 100 – 80). The
Contrast-value of the complementary scores (Ci) is −0.500
(= (20 – 60)/(20 + 60)).
The use of TDC when a priori knowledge of an item’s
unimpaired value is lacking
The question is how to determine a Contrast-value when
the value of a score corresponding to ‘least impairment’ is
unknown. For example, due to pathology of the Temporo-
mandibular joint, a patient of the type of artrogenous
TMD might have a restricted ability to open the mouth
maximally. Apart from pain variables, the extent of max-
imal mouth opening is then a key factor to include in TDC
for controlling treatment duration. However, the unre-
stricted maximal mouth opening is a priori not known for
a particular patient. An approximate Contrast-value might
then be determined by taking, at least initially, a lower 95%
confidence limit (CL) of normal values (determined in a
group of healthy subjects) as score value for unrestricted
maximal mouth opening, thus SCL-normal is initially taken
as the maximum score value of the scale, Smax. Because,
like score values from a quality of life scale (see above, Ap-
pendix section ‘The use of TDC on scales with a reversed
meaning’), a larger score value of mouth opening is related
to less impairment, the first and the second score are again
transformed to complementary values according to: S1,i’ =
Smax - S1,i and S2,i’ = Smax - S2,i, in which Smax = SCL-normal.
The Contrast-value Ci for maximal mouth opening is then
given by Ci = (S2,i’ - S1,i’)/(S2,i’ + S1,i’). When a patient’s
value of S2,i would become larger than SCL-normal in a late
phase of treatment, Smax in the transformation equationmight then be replaced by this S2,i value for improving the
estimated Contrast-value for the actual visit and subse-
quent visits.
For example, suppose that the patient’s score values for
mouth opening are 20 mm (S1,i) before and 30 mm halfway
treatment (S2,i). With a lower 95% confidence limit for nor-
mal values of 35 mm [36], initially taken as Smax, the com-
plementary values related to ‘extent of impairment of mouth
opening’ are then S1,i’ = 15 (= 35–20) and S2,i’= 5 (= 35–30).
The Contrast-value of the complementary scores (Ci) is
−0.500 (= (5–15)/(5 + 15)). Suppose that S2,i becomes
43 mm at the end of treatment reflecting that the patient’s
value has entered the 95% range of normal values (between
35 and 45 mm). This novel value of S2,i is then taken as
Smax, the complementary values are then S1,i’ = 23 (= 43–
20) and S2,i’ = 0 (= 43–43), and Ci will be −1 (= (0–23)/ (0
+ 23)) indicating a lack of any impairment with respect to
the ability of opening the mouth maximally.
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